Aproxetine for treatment of multi-system atrophy
By using aproxetine or its pharmaceutically acceptable salts for long-term treatment of orthostatic hypotension in patients with multiple system atrophy, the problems of significant side effects and unstable pharmacokinetics associated with existing drugs have been resolved, resulting in symptom relief and improved quality of life.
Patent Information
- Application Number
- CN202380028690.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-28
- Filing Date
- 2023-03-28
- Publication Date
- 2024-11-15
AI Technical Summary
Existing drugs for treating neurogenic orthostatic hypotension (nOH) caused by multiple system atrophy have serious side effects, unstable pharmacokinetics, and insignificant efficacy, especially in patients with multiple system atrophy (MSA).
Aproxetine or its pharmaceutically acceptable salts, administered to patients orally or otherwise, for at least 8 to 22 weeks, are used to increase norepinephrine levels and alleviate symptoms.
It significantly alleviated symptoms such as dizziness, lightheadedness, and vertigo in patients with multiple system atrophy, improved their quality of life, and maintained stable pharmacokinetic properties during long-term treatment.
Smart Images

Figure CN118973577A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 324,313, filed on March 28, 2022, under 35 U.S.C. §119(e), which is hereby incorporated by reference in its entirety. Technical Field
[0003] The present application discloses a method of using ampreloxetine or a pharmaceutically acceptable salt thereof to treat an individual suffering from multiple system atrophy (MSA). The disclosed method includes using ampreloxetine or a pharmaceutically acceptable salt thereof to: (i) treat symptoms of neurogenic orthostatic hypotension in an individual suffering from MSA; (ii) reduce the extent of the decline in the quality of life of an individual suffering from MSA; and / or (iii) increase the level of norepinephrine in an individual suffering from MSA. Background Art
[0004] Neurogenic orthostatic hypotension (nOH) is a form of orthostatic hypotension (OH) and is a highly relevant symptom of multiple system atrophy (MSA) or Parkinson's Disease (PD). nOH is caused by central or peripheral nervous system disorders, such as MSA or PD, respectively. Such disorders can cause a deficiency or disorder of norepinephrine, which is the main neurotransmitter that regulates blood pressure in response to posture changes (Loavenbruck et al., Curr. Med. Res. Opin., 2015; 31: 2095-2104). As a result, the autonomic nervous system is unable to properly regulate blood pressure during posture changes, and the patient experiences a significant drop in blood pressure, resulting in, for example, dizziness, weakness, fatigue, blurred vision, inattention, head and neck discomfort, or syncope.
[0005] Therefore, one goal of nOH treatment is to increase the patient's norepinephrine level. One way to increase norepinephrine levels is to administer an agent that produces norepinephrine. For example, droxidopa (L-threo-3-4-dihydroxyphenylserine) is an amino acid that is converted to norepinephrine by decarboxylation in the central and peripheral nervous systems, thereby increasing norepinephrine levels (Kaufmann et al., Circulation, 2003; 108: 724-728; Kaufmann, Clin. Auton. Res. (2008) 18 [Suppl 1]: 19-24); and Isaacson et al., Vascular Health and Risk Management, 2014, 10: 169-176). In the United States, droxidopa is approved for the treatment of orthostatic dizziness, lightheadedness, or "feeling like you're going to pass out" in adult patients with symptomatic nOH caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. The major side effect of droxidopa is supine hypertension, and its prescribing information includes a boxed warning due to this serious side effect. In addition, the prescribing information for droxidopa states that the effectiveness of treatment beyond 2 weeks has not been established.
[0006] Alternatively, norepinephrine levels can be increased by inhibiting the norepinephrine transporter responsible for norepinephrine reuptake. For example, atomoxetine is a selective norepinephrine reuptake inhibitor approved in the United States for the treatment of attention deficit hyperactivity disorder (ADHD). Atomoxetine has been shown to increase blood pressure in patients with central autonomic failure (Ramirez et al., Hypertension, 2014; 64: 1235-40; and Shibao et al., Hypertension, 2007; 50: 47-53). However, atomoxetine is primarily metabolized via the CYP2D6 enzyme pathway, and therefore its pharmacokinetic properties vary depending on whether an individual has reduced CYP2D6 activity (poor metabolizers) or normal CYP2D6 activity (excessive metabolizers) (Ring et al., Drug Metabolism and Distribution, 2002, 30:319-323). In addition, when used to treat ADHD, atomoxetine is associated with a variety of gastrointestinal adverse effects, including dry mouth and nausea. Atomoxetine has not yet been approved for the treatment of nOH. In addition, in recent studies, atomoxetine has been shown to be ineffective for nOH in MSA patients, while showing an improvement in non-MSA patients (Urechie et al., Hypertension, 2022;79[Suppl 1]:AP063-AP063).
[0007] The α1-adrenergic receptor agonist midodrine is the only other drug approved by the FDA for the treatment of symptomatic nOH, and other agents used to treat nOH include the synthetic mineralocorticoid fludrocortisone and the cholinesterase inhibitor pyridostigmine. Side effects of these agents may include: supine hypertension, paresthesias (including scalp tingling), piloerection (goosebumps), and urinary urgency or retention with midodrine; hypokalemia, headache, peripheral edema, heart failure, and supine hypertension with fludrocortisone; and abdominal discomfort and urinary urgency with pyridostigmine.
[0008] Therefore, it is desirable to have additional options for treating nOH, particularly for patients with MSA. In particular, it would be desirable to provide an agent for treating nOH that is safe and well tolerated, has a predictable pharmacokinetic profile, and is also desirable to provide an agent that is effective for a longer period of time and in various patient subgroups. Summary of the invention
[0009] It has been found that when individuals with multiple system atrophy are treated with aproxetine, certain symptoms associated with nOH are surprisingly reduced over a longer period of time. For example, in individuals with multiple system atrophy and symptomatic neurogenic orthostatic hypotension, treatment with aproxetine for at least about 22 weeks surprisingly causes a measurable reduction in both: (i) the individual's symptoms of dizziness, lightheadedness, feeling faint or feeling like they might pass out; and (ii) the individual's overall impression of symptom severity. In addition, when individuals with multiple system atrophy are treated with aproxetine for at least about 22 weeks, the decline in the individual's quality of life can be reduced. Surprisingly, it has also been found that when individuals with multiple system atrophy are treated with aproxetine daily, the individual's norepinephrine levels continue to increase for at least about 8 weeks.
[0010] Therefore, the present disclosure provides a method of treating an individual with multiple system atrophy using aproxetine or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising aproxetine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The methods disclosed herein include, but are not limited to, using aproxetine or a pharmaceutically acceptable salt thereof to: (i) treat symptoms of neurogenic orthostatic hypotension in an individual with multiple system atrophy; (ii) reduce the magnitude of the decline in the quality of life of an individual with multiple system atrophy; and / or (iii) increase norepinephrine levels in an individual with MSA.
[0011] In one aspect, the present disclosure relates to a method for treating symptomatic neurogenic orthostatic hypotension (nOH) in a subject with multiple system atrophy (MSA), the method comprising administering to the subject daily for at least about 8 weeks a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof, wherein the administration results in a decrease in at least one of the Orthostatic Hypotension Symptom Assessment (OHSA) composite score, the Orthostatic Hypotension Daily Activities Scale (OHDAS) Item 1 score (short duration standing), and the OHDAS Item 3 score (short duration walking).
[0012] In some embodiments, the pharmaceutical composition is administered to the individual orally and / or once a day. In some embodiments, the individual treated has symptoms of neurogenic orthostatic hypotension without treatment with the pharmaceutical composition, as determined using the Orthostatic Hypotension Assessment Scale (OHSA). In some embodiments, the individual suffers from MSAP subtype (MSA-P) or MSA C subtype (MSA-C). In some embodiments, prior to the administration, the individual's BP continues to drop by ≥20 mmHg (systolic blood pressure) or ≥10 mmHg (diastolic blood pressure) within 3 minutes of standing as part of the upright standing test or tilting upward from a supine position by a tilt table test of ≥60°. In some embodiments, prior to treatment, prior to the administration, the individual's unified multiple system atrophy rating scale (UMSARS) Part IV score is 4 or less. In some embodiments, prior to the administration, the individual's OHSA Item 1 score is at least 4. In some embodiments, the pharmaceutical composition is administered for at least about 12 weeks. In some embodiments, aproxetine is administered in the form of a hydrochloride. In some embodiments, the pharmaceutically acceptable carrier comprises one or more of microcrystalline cellulose, lactose, and magnesium stearate.
[0013] In one aspect, the present disclosure relates to a method for treating symptomatic neurogenic orthostatic hypotension (nOH) in a subject with multiple system atrophy (MSA), the method comprising administering to the subject daily for at least about 22 weeks a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof, wherein:
[0014] (a) the individual being treated experiences symptoms of neurogenic orthostatic hypotension in the absence of treatment with the pharmaceutical composition, as determined using the Orthostatic Hypotension Assessment Scale (OHSA); and
[0015] (b) daily administration of the pharmaceutical composition to the subject for at least about 22 weeks causes a measurable decrease in at least one of: (i) the subject's OHSA composite score, (ii) Orthostatic Hypotension Questionnaire (OHQ) composite score, (iii) Orthostatic Hypotension Daily Activities Scale (OHDAS) composite score, or (iv) OHDAS Item 1 (Short-term Standing).
[0016] In some embodiments, the pharmaceutical composition is administered to the individual orally. In some embodiments, the pharmaceutical composition is administered to the individual once a day. In some embodiments, prior to treatment with the pharmaceutical composition, the individual's supine plasma norepinephrine level is less than about 350 pg / mL. In some embodiments, after about 8 weeks of treatment with the pharmaceutical composition, the individual's supine plasma norepinephrine level is greater than about 500 pg / mL. In some embodiments, the individual suffers from MSA P subtype (MSA-P). In some embodiments, prior to the administration, the individual has been diagnosed with MSA for at least 1.3 years. In some embodiments, the individual has nOH 1.6 years or more prior to the administration. In some embodiments, prior to the administration, the individual's OSHA composite score is 5 or higher. In some embodiments, prior to the administration, the individual's OSHA Item 1 score is 7 or higher. In some embodiments, prior to the administration, the individual's Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score is ≤4. In some embodiments, prior to said administering, said individual has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of 4. In some embodiments, aproxetine is administered in the form of a hydrochloride salt. In some embodiments, said pharmaceutical composition is administered for at least about 12 months. In some embodiments, said pharmaceutically acceptable carrier comprises one or more of microcrystalline cellulose, lactose, and magnesium stearate.
[0017] In one aspect, the present disclosure relates to a method of identifying an individual with multiple system atrophy (MSA) who is responsive to aproxetine, comprising administering to the individual a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof for at least 8 weeks.
[0018] In some embodiments, the pharmaceutical composition is administered for at least 12 weeks. In some embodiments, the method further comprises determining whether the individual's Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 score after said administration is reduced by at least 2 points. In some embodiments, the pharmaceutical composition is administered to the individual orally. In some embodiments, the pharmaceutical composition is administered to the individual once a day. In some embodiments, the MSA is MSA P subtype (MSA-P) or MSA C subtype (MSA-C).
[0019] In one aspect, a method of treating symptomatic neurogenic orthostatic hypotension (nOH) in a subject with multiple system atrophy (MSA) comprises administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and aproxetine or a pharmaceutically acceptable salt thereof, wherein the subject:
[0020] (a) an Orthostatic Hypotension Assessment Scale (OSHA) composite score of 5 or greater prior to said administration; and / or
[0021] (b) An OSHA Section 1 rating of 7 or higher prior to said administration.
[0022] Also provided herein is the use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof for treating symptomatic neurogenic orthostatic hypotension (nOH) in an individual with multiple system atrophy (MSA).
[0023] Other aspects and embodiments are disclosed herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Various aspects of the disclosure are explained with reference to the accompanying drawings.
[0025] Figure 1A Shown are OHSA Item 1 scores for subjects with multiple system atrophy administered aproxetine or placebo at the end of the 6-week double-blind randomized period.
[0026] Figure 1B Shown are OHSA composite scores for subjects with multiple system atrophy administered aproxetine or placebo at the end of the 6-week double-blind randomized period.
[0027] Figure 2A Shown are OHDAS composite scores for subjects with multiple system atrophy administered aproxetine or placebo at the end of the 6-week double-blind randomized period.
[0028] Figure 2B Shown are the mean changes in systolic blood pressure in subjects with multiple system atrophy administered aproxetine or placebo at the end of the 6-week double-blind randomized period.
[0029] Figure 3 Shown are OHSA and OHDAS composite scores and individual subscores for symptoms and daily activities for subjects with multiple system atrophy administered aproxetine or placebo at the end of the 6-week double-blind randomized period.
[0030] Figure 4 Shown are the mean EQ-VAS scores for individuals with multiple system atrophy at each treatment week.
[0031] Figure 5 Shown is the mean difference in OHSA composite scores between aproxetine and placebo in the subgroup of individuals with multiple system atrophy administered aproxetine or placebo at the end of the 6-week double-blind randomized period.
[0032] Figure 6 Shown is the mean difference in OHQ composite score between aproxetine and placebo in the subgroup of individuals with multiple system atrophy administered aproxetine or placebo at the end of the 6-week double-blind randomized period. DETAILED DESCRIPTION
[0033] In various aspects and embodiments, the present application discloses methods of using aproxetine or a pharmaceutically acceptable salt thereof to treat an individual suffering from multiple system atrophy.
[0034] definition
[0035] When describing the various aspects and embodiments disclosed herein, the following terms have the following meanings unless otherwise indicated.
[0036] Unless the context of use clearly dictates otherwise, the singular terms "a," "an," and "the" include the corresponding plural terms.
[0037] The term "about" means ±5% of the specified value.
[0038] The term "melting point" means the temperature at which the maximum endothermic heat flow corresponding to the thermal transition of a solid to liquid phase change is observed by differential scanning calorimetry.
[0039] The term "pharmaceutically acceptable" means acceptable for administration to a subject (eg, having an acceptable safety profile for an intended use).
[0040] The term "pharmaceutically acceptable salts" means salts prepared from acids and bases (including zwitterions) that are acceptable for administration to a subject (eg, salts having an acceptable safety profile for a given dosage regimen).
[0041] The term "subject" means a human individual or patient.
[0042] The term "therapeutically effective amount" means an amount sufficient to effect treatment when administered to a subject in need of treatment, eg, the amount required to achieve the desired therapeutic effect.
[0043]
[00136] The terms "treating" or "treatment" mean to improve or inhibit the medical condition or disorder being treated; or to alleviate the symptoms of a medical condition or disorder.
[0044] The term "unit dosage form" or "unit dose" means a physically discrete unit suitable for administration to an individual, i.e., each unit contains a predetermined quantity of therapeutic agent calculated to produce a therapeutic effect alone or in combination with one or more additional units. Examples include capsules, tablets, etc.
[0045] The term "sitting systolic blood pressure" means the systolic blood pressure recorded after 5 and 10 minutes of sitting.
[0046] The term "standing systolic blood pressure" means the systolic blood pressure recorded after standing for 1, 3, 5 and 10 minutes.
[0047] All other terms used herein are intended to have their ordinary meanings as understood by one of ordinary skill in the art to which they belong.
[0048] Compounds of formula I
[0049] Aproxetine or 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine is a norepinephrine reuptake inhibitor having the formula I:
[0050]
[0051] See, e.g., Smith et al., Int J Neuropsychopharmacol. 2015; 18(2) pyu 027. Aproxetine is also known as TD-9855.
[0052] U.S. Patent Nos. 8,304,432, 8,604,058, 9,162,982, 9,675,599, 10,034,870, 10,306,913, 10,441,579, 10,722,504 and 10,946,007 disclose 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds, including aproxetine and pharmaceutically acceptable salts thereof. In addition, U.S. Patent Nos. 8,304,433, 8,592,596, 9,073,859, 10,226,454, 10,576,073 and 10,946,006 disclose crystalline hydrochloride salts of aproxetine. These patents disclose various uses of aproxetine and its salts, including treatment of pain disorders, depression, cognitive impairment, stress urinary incontinence, chronic fatigue syndrome, obesity, vasomotor symptoms associated with menopause, chronic low back pain, osteoarthritis and other conditions.
[0053] US Patent No. 10,238,642 discloses methods of using aproxetine and pharmaceutically acceptable salts thereof to treat neurogenic orthostatic hypotension (nOH) and its symptoms in human patients suffering from multiple system atrophy (MSA), Parkinson's disease (PD) or pure autonomic failure (PAF).
[0054] Aproxetine has been evaluated in several clinical trials. For example, single ascending dose studies were conducted in healthy individuals at doses ranging from 2 to 50 mg, and multiple ascending dose studies were conducted in healthy individuals at daily doses of 4, 10, 20, and 40 mg for up to 14 days to evaluate the safety and tolerability of aproxetine. In healthy individuals, single doses up to 50 mg and multiple doses up to 20 mg once daily were generally well tolerated.
[0055] The safety, tolerability, and efficacy of aproxetine were also evaluated in two Phase 2 studies in individuals with attention deficit hyperactivity disorder and fibromyalgia. In both studies, aproxetine doses of 5 mg or 20 mg were administered once daily for 6 weeks, and aproxetine was generally well tolerated with no clinically significant safety signals.
[0056] In these studies, the maximum concentration (C max The pharmacokinetic (PK) properties of aproxetine are linear with near dose-proportional exposure for both the t-value and area under the curve (AUC). 1 / 2 ) is about 30 to 40 hours, and steady state is reached after 6 days. Consistent with the elimination half-life, 3 to 4 times of aproxetine accumulation was observed at steady state. Based on clinical PK studies in healthy individuals, >90% of aproxetine is eliminated by metabolism, of which cytochrome P450 1A2 (CYP1A2) is the main enzyme responsible for aproxetine metabolism. See, for example, Kanodia et al., "Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit / Hyperactive Disorder or Fibromyalgia Pain", Clinical Pharmacokinetics, (2021) 60: 121-131.
[0057] Aproxetine was also evaluated in a multicenter, randomized, three-part (single-blind (Part A), double-blind, placebo-controlled (Part B), and open-label multiple-dose extension (Part C)) Phase 2 study in individuals with symptomatic nOH. Part A evaluated the dose response of aproxetine at single ascending doses up to 20 mg. Although no dose response was observed, a numerical trend toward increased sitting and standing systolic blood pressure (SBP) was observed at higher doses. An improvement in standing time of approximately 100 seconds was observed 4 hours after dosing with 10 mg. In Part B, individuals were treated with aproxetine (up to 15 mg) in a double-blind, placebo-controlled, 1-day inpatient study. Individuals receiving aproxetine showed a sustained increase in SBP compared to baseline after standing for 3 minutes 4 hours and 7 hours after dosing. At these time points, no increase in SBP was observed in placebo-treated individuals. See, e.g., Kaufman et al., Clin Autolog Res (2021) 31:699-711; and Kaufman et al., “A Phase 2, Dose-Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies,” Poster 126 presented at the International Parkinson and Movement Disorder Society; September 22-26, 2019; Nice, France.
[0058] Part C of this study evaluated the durability of response, safety, and tolerability of aproxetine in an open-label, Phase 2, multicenter study in individuals with nOH. Individuals were treated with oral aproxetine (3-20 mg) once daily for up to 20 weeks and followed up for 4 weeks after stopping aproxetine treatment. The primary efficacy endpoint of Part C was an improvement of at least 2 points from baseline in the Orthostatic Hypotension Symptom Assessment (OHSA) Question 1 (OHSA#1) score. OHSA#1 measures dizziness, lightheadedness, feeling faint, or feeling like you're going to pass out. The majority of individuals achieved this endpoint. See, e.g., Kaufman et al., Clinical Autonomic Research (2021) 31:699-711; and Kaufman et al., “Efficacy, Durability, and Safety of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Primary Autonomic Failure,” in World Congress on Parkinson's Disease and Related Disorders. Related Disorders; June 16-19, 2019; Montreal, Canada; and Kaufman et al., “A Phase 2 study of the Efficacy, Durability, and Safety of Ampreloxetine(TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension(nOH) in Subjects with Synucleinopathies,” Poster 125 presented at the International Parkinson and Movement Disorders Society; September 22-26, 2019; Nice, France.
[0059] Recently, aproxetine was evaluated in two Phase 3 studies. The first Phase 3 study was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study designed to evaluate its efficacy, safety, and tolerability after 4 weeks of treatment in individuals with primary autonomic failure (MSA, PD, or PAF) and symptomatic nOH. The primary objective of this study was to evaluate the efficacy of aproxetine in individuals with MSA, PD, or PAF who experienced symptomatic nOH compared to placebo at 4 weeks, as measured by the change from baseline in the OHSA#1 score. After 4 weeks of treatment, the study did not meet the primary endpoint.
[0060] The second Phase 3 study was a multicenter, randomized discontinuation study to evaluate the sustained benefit of aproxetine in efficacy and safety after 22 weeks of treatment in subjects with primary autonomic failure (MSA, PD, or PAF) and symptomatic nOH. The study consisted of a 16-week open-label (OL) aproxetine treatment period followed by a 6-week double-blind randomized discontinuation period in which subjects were administered aproxetine or placebo.
[0061] Aspects and embodiments disclosed herein employ aproxetine (TD-9855 or 4-[2-(2,4,6-trifluorophenoxy-methyl)phenyl]piperidine) having Formula I:
[0062]
[0063] or a pharmaceutically acceptable salt thereof.
[0064] Aproxetine and its intermediates can be prepared as described in the Examples herein, or by the methods and procedures disclosed in U.S. Pat. Nos. 8,304,432, 8,304,433, 8,247,433, and 10,640,467, which are incorporated herein by reference, and related patents.
[0065] In some embodiments, aproxetine is used in the form of a pharmaceutically acceptable salt. Representative pharmaceutically acceptable salts include salts of the following acids (wherein the corresponding anions are shown in parentheses): acetic acid (acetate), ascorbic acid (ascorbate), benzenesulfonic acid (benzenesulfonate or besylate), benzoic acid (benzoate), camphorsulfonic acid (camphorsulfonate), chlorophylline (chlorophylline ion), citric acid (citrate), ethanesulfonic acid (ethanesulfonate), ethanedisulfonic acid (ethanedisulfonic) or ethanedisulfonic acid (edisylic) (ethanedisulfonic acid ethanedisulfonate or edisylate), fumaric acid (fumarate), gentisic acid (gentisate), gluconic acid (gluconate), glucuronic acid (glucuronate), glucoheptonic acid (glucoheptonate), glutamic acid (glutamate), hippuric acid (hippurate), hydrobromic acid (bromide), hydrochloric acid (chloride), hydroiodic acid (iodide), isethionic acid (isothionate), lactic acid (lactate), lactobionic acid (lactobionate), lauryl sulfonic acid (lauryl sulfonate), maleic acid (maleate), Malic acid (malate), mandelic acid (mandelate), methanesulfonic acid (methanesulfonate or mesylate), methylsulfonic acid (methylsulfonate), mucic acid (mucate), naphthalenesulfonic acid (naphthalenesulfonate or napsylate), naphthalene-1,5-disulfonic acid (naphthalene-1,5-disulfonate), naphthalene-2,6-disulfonic acid (naphthalene-2,6-disulfonate), naphthoic acid (naphthoate), nicotinic acid (nicotinate), nitric acid Such salts are sometimes referred to as acid addition salts.
[0066] The salt can be prepared by contacting one molar equivalent of aproxetine with about 0.95 to about 1.05 molar equivalents of acidic protons in a pharmaceutically acceptable acid. For example, 1 molar equivalent of aproxetine can be contacted with about 1 molar equivalent of hydrochloric acid to form aproxetine hydrochloride; or 1 molar equivalent of aproxetine can be contacted with about 0.5 molar equivalent of sulfuric acid to form aproxetine sulfate.
[0067] These reactions are typically carried out in a diluent (e.g., dichloromethane, ethanol, ethyl acetate, isopropyl acetate, water, etc.) at a temperature in the range of about -20°C to about 65°C for about 0.5 to about 12 hours or until the reaction is substantially complete. After the reaction is complete, the product is typically isolated using conventional procedures such as filtration, chromatography, recrystallization, etc. The products of these reactions may or may not be crystalline.
[0068] In some embodiments, a protected derivative of aproxetine (e.g., tert-butyl 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine-1-carboxylate) is contacted with a pharmaceutically acceptable acid (e.g., hydrochloric acid) to remove the protecting group and form a pharmaceutically acceptable salt of aproxetine.
[0069] In some embodiments, the compound employed is aproxetine hydrochloride. In another embodiment, the compound is a crystalline hydrochloride of aproxetine, characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 4.44±0.2, 10.22±0.2, and 21.78±0.2. In another embodiment, the crystalline hydrochloride is further characterized by having one or more additional diffraction peaks at 2θ values selected from 8.11±0.2, 13.18±0.2, 16.06±0.2, 17.16±0.2, 18.38±0.2, 23.76±0.2, 26.32±0.2, 27.24±0.2, 29.60±0.2, and 31.94±0.2. In another embodiment, the compound is a crystalline hydrochloride of aproxetine, characterized by a differential scanning calorimetry trace with a melting point of about 197±2°C.
[0070] In some embodiments, the crystalline hydrochloride salt of aproxetine contains about 0 wt % to about 2 wt % water, for example, the crystalline hydrochloride salt adsorbs or desorbs water based on relative humidity.
[0071] The crystalline hydrochloride salt of aproxetine employed may be prepared as described in the Examples herein, or by the methods and procedures disclosed in US Pat. Nos. 8,304,432, 8,304,433, and 8,247,433 and related patents.
[0072] Pharmaceutical compositions, preparations and dosage forms
[0073] When used as disclosed herein, aproxetine or a pharmaceutically acceptable salt thereof is typically administered to an individual or patient in the form of a pharmaceutical composition or formulation. When describing the composition or formulation herein, aproxetine or a pharmaceutically acceptable salt thereof may be referred to as an "active agent" to distinguish it from other components of the formulation (e.g., carriers or excipients). Therefore, the term "active agent" includes aproxetine and a pharmaceutically acceptable salt thereof. In addition, unless otherwise indicated, the terms "carrier" and "excipient" are used interchangeably herein and have the same meaning.
[0074] Pharmaceutical compositions generally contain a therapeutically effective amount of an active agent. However, one skilled in the art will recognize that a pharmaceutical composition may contain more than a therapeutically effective amount, such as a bulk composition, or less than a therapeutically effective amount, such as a single unit dose designed for multiple administrations to achieve a therapeutically effective amount.
[0075] Typically, the pharmaceutical composition will contain from about 0.01% to about 95% by weight of the active agent, including from about 0.01% to about 30% by weight, such as from about 0.01% to about 10% by weight, where the actual amount depends on the formulation, route of administration, frequency of administration, etc. For example, a pharmaceutical composition suitable for use as an oral dosage form may contain from about 0.1% to about 10% by weight (including from about 0.5% to about 5%) of the active agent.
[0076] In a representative embodiment, the pharmaceutical composition contains about 0.5 mg to about 20 mg of active agent per unit dose, including about 1 mg to about 10 mg of active agent per unit dose. For example, the active agent can be formulated into 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg unit doses, such as 1 mg, 3 mg, 5 mg, 10 mg and 15 mg unit doses (wherein each amount refers to the free base equivalent of aproxetine). In a specific embodiment, the pharmaceutical composition contains about 10 mg of active agent (free base equivalent) per unit dose.
[0077] Any conventional or suitable pharmaceutically acceptable carrier can be used in pharmaceutical compositions. The selection of a specific carrier or carrier combination will depend on various factors, such as mode of administration, dosage, frequency of administration, release time of active agent, etc. In this regard, the preparation of a suitable pharmaceutical composition for a specific mode of administration is completely within the capabilities of a technician in the pharmaceutical field, and the carrier for such compositions is commercially available. In a further illustrative manner, conventional preparations and formulation techniques are described in, for example, Remington: The Science and Practice of Pharmacy, 23rd edition, Academic Press, Cambridge, MA (2020); and Loyd V. Allen, Jr. et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 11th edition, Lippincott Williams & Wilkins, Philadelphia, PA (2017).
[0078] Representative examples of pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; celluloses such as microcrystalline cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered solutions; compressed propellant gases such as chlorofluorocarbons and hydrofluorocarbons; and other nontoxic compatible substances used in pharmaceutical compositions.
[0079] Pharmaceutical compositions are generally prepared by thoroughly and intimately mixing or admixing the active agent with a pharmaceutically acceptable carrier and any optional ingredients. The resulting uniformly blended mixture can then be formed or loaded into tablets, capsules, pills, cans, cartridges, vials, bottles, dispensers, etc. using conventional procedures and equipment.
[0080] In some embodiments, the pharmaceutical composition is suitable for oral administration. The pharmaceutical composition for oral administration can be in the form of, for example, capsules, tablets, pills, lozenges, cachets, dragees, powders, granules, solutions, suspensions, emulsions, elixirs, syrups, etc.; each form contains a predetermined amount of active agent.
[0081] When intended for oral administration in a solid dosage form (eg, capsules, tablets, etc.), the pharmaceutical composition will generally comprise the active agent and one or more pharmaceutically acceptable solid carriers, such as sodium citrate or dicalcium phosphate. Solid dosage forms may also contain: fillers or extenders such as starch, microcrystalline cellulose, lactose, sucrose, glucose, mannitol and / or silicic acid; binders such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; humectants such as glycerol; disintegrants such as cross-linked sodium carboxymethylcellulose, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and / or sodium carbonate; solution retardants such as paraffin; absorption promoters such as quaternary ammonium compounds; wetting agents such as cetyl alcohol and / or glyceryl monostearate; adsorbents such as kaolin and / or bentonite clay; lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and / or mixtures thereof; colorants; buffers; release agents; coating agents; sweeteners, flavoring agents and / or perfuming agents; or preservatives and / or antioxidants.
[0082] Representative coating agents for tablets, capsules, pills and the like include those for enteric coatings, such as cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, methacrylic acid-methacrylate copolymer, cellulose acetate trimellitate, carboxymethyl ethyl cellulose, hydroxypropyl methylcellulose acetate succinate, polyvinyl alcohol and the like.
[0083] Representative antioxidants include: water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate, sodium sulfite, etc.; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, lecithin, propyl gallate, α-tocopherol, etc.; and metal chelators, such as citric acid, ethylenediaminetetraacetic acid, sorbitol, tartaric acid, phosphoric acid, etc.
[0084] Pharmaceutical composition can also be prepared using, for example, hydroxypropylmethylcellulose or other polymer matrix, liposome and / or microsphere of different proportions, to provide slow or controlled release of activating agent. In addition, pharmaceutical composition can contain emulsifier, and can be formulated to make the pharmaceutical composition only or preferentially release activating agent in a certain part of gastrointestinal tract in a delayed manner. The example of spendable embedded composition includes polymeric substance and wax. Activating agent can also be in microencapsulation form with one or more of the above-mentioned excipients when applicable.
[0085] Suitable liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. Liquid dosage forms typically include active agents and inert diluents, such as water, fruit juice or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (e.g., cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuran alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof. Suspensions may contain suspending agents, such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth, and mixtures thereof.
[0086] In another embodiment, the pharmaceutical composition is suitable for topical administration, such as transdermal administration. For such administration, known transdermal delivery systems and excipients can be used. For example, the active agent can be mixed with a penetration enhancer (e.g., propylene glycol, polyethylene glycol monolaurate, azacycloalkane-2-one, etc.) and incorporated into a patch or similar delivery system. If necessary, additional excipients can be used in such transdermal compositions, including gelling agents, emulsifiers, and buffers.
[0087] In another embodiment, the pharmaceutical composition is suitable for parenteral administration (e.g., by subcutaneous, intravenous, intramuscular or intraperitoneal injection). For such administration, the active agent is provided in the form of a sterile solution, suspension or emulsion. Exemplary carriers for preparing such preparations include water, saline, low molecular weight alcohols (e.g., propylene glycol, polyethylene glycol), oils, gelatin, fatty acid esters (e.g., ethyl oleate), etc. Parenteral preparations may also contain one or more solubilizers, stabilizers, preservatives, wetting agents, emulsifiers and dispersants. These preparations may be sterilized by using sterile injectable media, sterilizing agents, filtering, irradiation or heating.
[0088] Typical intravenous formulations are sterile pH 4-7 aqueous solutions containing the active agent and a physiologically acceptable aqueous carrier. Representative physiologically acceptable aqueous carriers include, for example, Sterile Water for Injection, USP; Dextrose Injection, USP (e.g., 2.5%, 5.0%, 10%, 20% dextrose, including 5% Dextrose Injection (D5 / W)); Dextrose and Sodium Chloride Injection, USP (e.g., dextrose varying from 2.5% to 10% and sodium chloride varying from 0.12% (19 mEq sodium) to 0.9% (154 mEq sodium)); Mannitol Injection, USP (e.g., 5%, 10%, 15%, 20% and 25% mannitol); Ringer's Injection, USP (e.g., 147 mEq sodium, 4 mEq potassium, 4.5 mEq calcium and 156 mEq chloride per liter); Lactated Ringer's Injection, USP (e.g., 2.7 mEq calcium, 4 mEq potassium, 130 mEq sodium and 28 mEq lactate per liter); Sodium Chloride Injection, USP (e.g., 0.9% sodium chloride), etc. When administered to a subject, the active agent is typically diluted in about 0.1 mL to about 10 mL of an aqueous carrier per mg of the active agent, for example, in about 0.5 to about 5 mL per mg. The dosing solution is then typically administered to the subject by intravenous infusion.
[0089] For example, representative pharmaceutical compositions can be prepared as described in the following examples.
[0090] A. Hard gelatin capsules
[0091] Active agent (5 g), spray-dried lactose (485 g) and magnesium stearate (10 g) are thoroughly blended. The resulting composition is then filled into hard gelatin capsules (500 mg composition per capsule). Each capsule provides 5 mg of active agent per unit dose suitable for oral administration.
[0092] B. Hard gelatin capsules
[0093] The active agent (2 g) is thoroughly blended with starch (98 g), microcrystalline cellulose (98 g) and magnesium stearate (2 g). The mixture is then passed through a No. 45 mesh sieve and filled into hard gelatin capsules (200 mg composition per capsule). Each capsule provides 2 mg of active agent per unit dose suitable for oral administration.
[0094] C. Soft gelatin capsules
[0095] The active agent (5 g) is thoroughly blended with polyoxyethylene sorbitan monooleate (65 g) and starch powder (330 g). The mixture is then filled into soft gelatin capsules (400 mg composition per capsule). Each capsule provides 5 mg of active agent per unit dose suitable for oral administration.
[0096] D. Soft gelatin capsules
[0097] The active agent (1 g) is thoroughly blended with microcrystalline cellulose (290 g) and magnesium stearate (9 g). The mixture is then filled into soft gelatin capsules (300 mg composition per capsule). Each capsule provides 1 mg of active agent per unit dose suitable for oral administration.
[0098] E. tablet
[0099] Active agent (10 g), starch (45 g) and microcrystalline cellulose (35 g) are passed through a U.S. No. 20 mesh screen and mixed thoroughly. The resulting granules are dried at 50 to 60° C. and passed through a U.S. No. 16 mesh screen. Separately, polyvinylpyrrolidone solution (4 g, in the form of a 10% solution in sterile water) is mixed with sodium carboxymethyl starch (4.5 g), magnesium stearate (0.5 g) and talc (1 g), and this mixture is passed through a U.S. No. 16 mesh screen. The resulting mixture is then added to the granules. After being mixed thoroughly, the mixture is compressed on a tablet press to form tablets weighing 100 mg per tablet. Each tablet provides 10 mg of active agent per unit dose suitable for oral administration.
[0100] F. tablet
[0101] The active agent (40 g) is thoroughly blended with microcrystalline cellulose (445 g), fumed silicon dioxide (10 g) and stearic acid (5 g). The mixture is then compressed on a tablet press to form tablets weighing 100 mg each. Each tablet provides 8 mg of active agent per unit dose suitable for oral administration.
[0102] G. tablet
[0103] The active agent (10 g) is thoroughly blended with corn starch (50 g), croscarmellose sodium (25 g), lactose (110 mg) and magnesium stearate (5 mg). The mixture is then compressed on a tablet press to form tablets weighing 200 mg each. Each tablet provides 10 mg of active agent per unit dose suitable for oral administration.
[0104] H. tablet
[0105] Active agent (10 g) is thoroughly blended with corn starch (230 g) and aqueous gelatin solution (50 g). The mixture is dried and ground into a fine powder. Microcrystalline cellulose (100 g) and magnesium stearate (10 g) are then mixed with the gelatin preparation, granulated, and the resulting mixture is compressed on a tablet press to form tablets weighing 200 mg per tablet. Each tablet provides 5 mg of active agent per unit dose suitable for oral administration.
[0106] I. syrup
[0107] Mix the following ingredients thoroughly until all solid ingredients are dissolved:
[0108]
[0109] The resulting syrup contains 5 mg of active agent per 10 mL of syrup suitable for oral administration.
[0110] J. Sterile intravenous solution
[0111] The active agent (5 mg) is blended with 0.4 M sodium acetate buffer solution (2.0 mL). The pH of the resulting solution is adjusted to pH 4 using 0.5 N aqueous hydrochloric acid or 0.5 N aqueous sodium hydroxide as needed, and then sufficient water for injection is added to provide a total volume of 20 mL. The mixture is then filtered through a sterile filter (0.22 micron) to provide a sterile solution suitable for administration by intravenous infusion.
[0112] co-investment and combination
[0113] If desired, aproxetine or a pharmaceutically acceptable salt thereof may be administered in combination with one or more other therapeutic agents ("second agents").
[0114] Representative therapeutic agent classes that can be administered in combination with aproxetine or a pharmaceutically acceptable salt thereof include, for example, α1-adrenergic receptor (α1-adrenergic receptor) (α1-adrenoceptor) agonists, α2-adrenergic receptor (α2-adrenergic receptor) (α2-adrenoceptor) antagonists, corticosteroids, norepinephrine precursors, cholinesterase inhibitors, or combinations thereof. Those skilled in the art will understand that the terms "α1-adrenergic receptor agonists", "α2-adrenergic receptor antagonists", "corticosteroids", "norepinephrine precursors" and "cholinesterase inhibitors" include all forms of compounds that have a specified activity after administration to a subject, such as pharmaceutically acceptable salts, solvates, crystalline forms, polymorphs, prodrugs, etc. Similarly, the term "second agent" includes all forms of the second agent, such as pharmaceutically acceptable salts, solvates, crystalline forms, polymorphs, prodrugs, and the like.
[0115] Representative examples of α1-adrenergic receptor agonists include desglymidodrine, etilefrine, metaraminol, midodrine, etc., or in each case a pharmaceutically acceptable salt thereof. Midodrine is a prodrug of desglymidodrine, which is an α1-adrenergic receptor agonist. In some embodiments, the second agent is midodrine or a pharmaceutically acceptable salt thereof, such as midodrine hydrochloride.
[0116] Representative examples of the α2-adrenergic receptor antagonist include yohimbine and the like, or a pharmaceutically acceptable salt thereof.
[0117] Representative examples of corticosteroids include fludrocortisone, fludrocortisone acetate, and the like, or in each case a pharmaceutically acceptable salt thereof. Fludrocortisone acetate is a prodrug of fludrocortisone. In some embodiments, the second agent is fludrocortisone acetate.
[0118] Representative examples of norepinephrine precursors include droxidopa or a pharmaceutically acceptable salt thereof. In some embodiments, the second agent is droxidopa.
[0119] Representative examples of cholinesterase inhibitors include pyridostigmine or a pharmaceutically acceptable salt thereof. In some embodiments, the second agent is pyridostigmine or a pharmaceutically acceptable salt thereof, such as pyridostigmine bromide.
[0120] Aproxetine or its pharmaceutically acceptable salt and the second medicament can be physically mixed to form a composition containing two medicaments; or each medicament can be administered to an individual separately or simultaneously. For example, aproxetine or its pharmaceutically acceptable salt can be combined with a second medicament using conventional procedures and equipment to form a pharmaceutical combination comprising aproxetine or its pharmaceutically acceptable salt and the second medicament. In addition, the medicament can be combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition comprising aproxetine or its pharmaceutically acceptable salt, the second medicament and a pharmaceutically acceptable carrier. In this embodiment, the components of the composition are usually mixed or blended to produce a physical mixture. The physical mixture is then administered to an individual by any suitable route of administration, such as oral, topical or parenteral administration mode.
[0121] Alternatively, the medicaments may remain independent and different before being administered to an individual. In this embodiment, the medicaments are not physically mixed together before administration, but are administered simultaneously or at different times in the form of independent compositions. Such compositions may be packaged separately or may be packaged together in a kit. When administered at different times, the second medicament will generally be administered less than 24 hours after administration of aproxetine or its pharmaceutically acceptable salt, for example ranging from simultaneous administration to any time of about 24 hours after administration. This is also referred to as sequential administration. Thus, for example, aproxetine or its pharmaceutically acceptable salt may be administered orally simultaneously or sequentially with the second medicament using two tablets (e.g., one tablet for each active agent), wherein sequentially including administration immediately before or after administration of aproxetine or its pharmaceutically acceptable salt or administration at some other time (e.g., one hour before or after; or three hours before or after, etc.). Alternatively, the combination may be administered by different administration routes, such as one oral administration and another topical or parenteral administration.
[0122] When employed, the second agent is used in a therapeutically effective amount, i.e., an amount that produces a therapeutically beneficial effect when co-administered with aproxetine or a pharmaceutically acceptable salt thereof. For example, such agents are typically used in their approved doses. For example, midodrine hydrochloride is typically administered orally in an amount ranging from about 2.5 mg to about 10 mg, up to three times a day; and droxidopa is typically administered orally in an amount ranging from about 100 mg to about 600 mg, up to three times a day.
[0123] utility
[0124] Aproxetine or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) is being evaluated for treatment of individuals with multiple system atrophy. Multiple system atrophy (MSA), also known as Shy-Drager syndrome, is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the autonomic nervous system and movement. The initial symptoms of MSA are often difficult to distinguish from the initial symptoms of Parkinson's disease and include slow movements, tremors, or rigidity (rigidity); clumsiness or incoordination; speech disorders, hoarseness, tremors; dizziness or lightheadedness due to orthostatic hypotension; bladder control problems, such as a sudden urge to urinate or difficulty emptying the bladder. MSA is divided into two different types based on the symptoms that are most prominent when evaluating an individual: Parkinson's disease (MSA-P), whose main features are similar to those of Parkinson's disease (such as slow movement, rigidity and tremors), as well as problems with balance, coordination and autonomic nervous system dysfunction; and cerebellar type (MSA-C), whose main symptoms are characterized by ataxia (balance and coordination problems), difficulty swallowing, abnormal speech or trembling voice, and abnormal eye movements. The cause of MSA is still unclear. A notable feature of MSA is the accumulation of the protein alpha-synuclein in glial cells, which are cells that support nerve cells in the brain. These deposits of alpha-synuclein appear particularly in oligodendrocytes, a type of cell that produces myelin (a coating on nerve cells that enables them to conduct electrical signals quickly). A recent study suggests that the prion form of α-synuclein may be the cause of the disease (Prusiner et al., PNAS, (2015) 112: E5308-17).
[0125] MSA is characterized by degeneration of central autonomic pathways; however, peripheral postganglionic noradrenergic fibers and catecholamine reuptake mechanisms appear to be intact in MSA individuals, thus maintaining sympathetic tone (Biaggioni, Pharmacolgical Reviews (2017) 69(1):53-62). Normally, the increase in peripheral noradrenaline concentrations upon standing is counteracted by CNS sympatholytic activity mediated by noradrenaline-activated central α2-adrenergic receptors, thereby buffering the peripheral pressor effect and maintaining postural normotension. However, in MSA, intact peripheral sympathetic postganglionic adrenergic fibers are essentially “disconnected” from CNS regulation, thus fully exposing the pressor effect of noradrenaline. Although the residual sympathetic tone in these individuals cannot be modulated by baroreflex pathways or CNS inputs due to this “disconnection,” it can be targeted pharmacologically. Increasing peripheral sympathetic synaptic norepinephrine using aproxetine or a pharmaceutically acceptable salt thereof should induce a pressor effect in MSA individuals with nOH.
[0126] Aproxetine or a pharmaceutically acceptable salt thereof is generally administered to an individual in need of treatment in an amount ranging from about 0.5 mg to about 20 mg per day; or as needed. In some embodiments, the amount administered to an individual is in the range of about 1 mg to about 10 mg per day. In some embodiments, the amount administered to an individual is in the range of about 3 mg to about 10 mg per day. In some embodiments, the amount administered to an individual is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg per day, including 1 mg, 3 mg, 5 mg or 10 mg per day. In some embodiments, aproxetine or a pharmaceutically acceptable salt thereof is administered to an individual in an amount of about 10 mg per day. In some embodiments, aproxetine or a pharmaceutically acceptable salt thereof is administered to an individual in an amount of about 10 mg once a day. In some embodiments, aproxetine or a pharmaceutically acceptable salt thereof is administered to an individual in an amount of about 10 mg per day, wherein the 10 mg amount is the free base equivalent of aproxetine. The amount to be administered to a subject, the route of administration, and the frequency of administration will generally be determined by the physician treating the subject.
[0127] Aproxetine or a pharmaceutically acceptable salt thereof may be administered to a subject by any acceptable route of administration, including, for example, oral, topical (including transdermal), and parenteral (including intravenous) modes of administration.
[0128] In some embodiments, aproxetine or a pharmaceutically acceptable salt thereof is orally administered to a subject in a solid or liquid dosage form. In a specific embodiment, the form administered to a subject is a solid dosage form, including a tablet or capsule. In another specific embodiment, the form administered to a subject is a liquid dosage form, including a solution, syrup, suspension, or emulsion.
[0129] In another embodiment, the route of administration is topical.In a specific embodiment, the route of administration is transdermal administration using a transdermal patch.
[0130] In another embodiment, the route of administration is parenteral. In a specific embodiment, the route of administration is intravenous.
[0131] Aproxetine or a pharmaceutically acceptable salt thereof can be administered to an individual in a single daily dose (i.e., once a day); in multiple doses per day (e.g., twice, three times, or four times a day); or in multiple doses per week (e.g., twice, three times, four times, five times, or six times a week). Alternatively, the pharmaceutical composition can be administered continuously using, for example, a transdermal patch. In a specific embodiment, aproxetine or a pharmaceutically acceptable salt thereof is administered to an individual once a day.
[0132] Unlike other currently available therapies, aproxetine can be administered for a long time and shows an effect over a long period of time (e.g., more than two weeks). In some cases, according to the dosing regimen, aproxetine needs to be administered for a period of time to show an effect. For example, aproxetine or a pharmaceutically acceptable salt thereof is administered to an individual for at least about four weeks, at least about five weeks, at least about six weeks, at least about seven weeks, at least about eight weeks, at least about nine weeks, at least about ten weeks, at least about eleven weeks, at least about twelve weeks, at least about thirteen weeks, at least about fourteen weeks, at least about fifteen weeks, at least about sixteen weeks, at least about seventeen weeks, at least about eighteen weeks, at least about nineteen weeks, at least about twenty weeks, at least about twenty-one weeks, at least about twenty-two weeks, at least about twenty-three weeks, at least about twenty-four weeks, at least one year or at least two years. In some embodiments, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof can be administered for the aforementioned time period. Examples described herein illustrate some embodiments of such administration for a longer period of time.
[0133] In some embodiments, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof may be administered to a MSA patient or individual for at least about 8 weeks to treat nOH. Administration may be performed for at least about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, or about 24 weeks. In some embodiments, administration may be performed for longer periods of time, such as 6, 12, 18, and 24 months or longer.
[0134] This administration of aproxetine can result in an improvement in nOH symptoms, as evidenced by a decrease relative to baseline in one or more of the following: Orthostatic Hypotension Symptom Assessment (OHSA) Items 1, 2, 3, 4, 5, 6 and the composite score, Orthostatic Hypotension Daily Activities Scale (OHDAS) Items 1, 2, 3, 4 and the composite score, Orthostatic Hypotension Questionnaire (OHQ) composite score, and EQ-5D-5L Health Questionnaire scale score. In some embodiments, the decrease in OHSA (comprehensive or any individual item), OHDAS (comprehensive or any individual item), or OHQ composite score can be at least 1, 2, 3, or 4 points. Administration of aproxetine can result in an increase in sitting or standing systolic blood pressure (e.g., greater than about 20 mmHg), which may exceed the threshold for inducing syncope. In some embodiments, administration may result in improvement in one or more of the following: Patient Global Impression of Change (PGI-C), Patient Global Impression of Severity (PGI-S), Hospital Anxiety and Depression Scale (HADS) including anxiety total score, Columbia Suicide Severity Rating Scale (C-SSRS), UMSARS scale, COMPASS-31, Non-Motor Symptom Scale (NMSS), Burden Scale for Family Caregivers-short version (BSFC-s), fall incidence, and time to stand (e.g., 3 minutes or more).
[0135] Patients or individuals administered aproxetine may be selected from different patient / individual groups, and effects may be shown in a wide variety of patients / individuals (as demonstrated by the aforementioned parameters). For example, the patient or individual may have one or more of the following characteristics: male or female; at least 30 years old; less than 65 years old; at least 65 years old. Prior to treatment, the individual or patient may have the following: Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of less than 4; UMSARS Part IV score of 4; UMSARS Part IV score greater than 4; BP sustained decrease of ≥20 mmHg (systolic blood pressure) or ≥10 mmHg (diastolic blood pressure) within 3 minutes of tilting upward ≥60° from the supine position as determined by tilt table testing; OHSA Item 1 score of at least 3, 4, 5, 6 or 7; diagnosed as possible or probable MSA Parkinson's disease subtype (MSA-P) or cerebellar subtype (MSA-C); and / or plasma NE level>100 pg / mL after 30 minutes in a sitting position. In some embodiments, the individual or patient may have developed nOH less than about 0.5, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, or 3 years prior to treatment. In some embodiments, the individual or patient may have developed nOH at least about 0.5, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, or 3 years prior to treatment. In some embodiments, the individual or patient may have received a diagnosis of MSA less than about 0.5, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, or 3 years prior to treatment. In some embodiments, the individual or patient may have received a diagnosis of MSA at least about 0.5, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, or 3 years prior to treatment. In some embodiments, prior to treatment, the individual or patient may have an OHSA composite score of less than 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, prior to treatment, the individual or patient may have an OHSA composite score of at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, prior to treatment, the individual or patient may have an OHSA score of less than 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10 on item 1, 2, 3, 4, 5, or 6.In some embodiments, prior to treatment, the individual or patient may have an OHSA score of at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, prior to treatment, the individual or patient may have an OHDAS composite score of less than 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, prior to treatment, the individual or patient may have an OHDAS composite score of at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, prior to treatment, the individual or patient may have an OHDAS score of less than 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10 on item 1, 2, 3, or 4. In some embodiments, prior to treatment, the individual or patient may have an OHDAS score of at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, prior to treatment, the individual or patient may have an OHQ composite score of less than 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, prior to treatment, the individual or patient may have an OHQ composite score of at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.3, 4.5, 4.7, 5, 5.3, 5.5, 5.7, 6, 6.3, 6.5, 6.7, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, prior to administration, the individual or patient may have an Orthostatic Hypotension Assessment Scale (OSHA) composite score of 5 or more; and / or prior to administration, an OSHA Item 1 score of 7 or more.
[0136] In some embodiments, the individual or patient must not have a systemic disease that produces autonomic neuropathy, including but not limited to amyloidosis and autoimmune neuropathy and / or diabetes mellitus (DM). In some embodiments, the individual must not be known to be intolerant to other NRIs or SNRIs. The individual or patient must not be concomitantly using antihypertensive agents for the treatment of essential hypertension. In some embodiments, the individual or patient must not be concurrently using strong CYP1A2 inhibitors or inducers, midodrine or droxidopa. In some embodiments, the individual or patient must not be known or suspected to have the following: alcohol or drug abuse; clinically unstable coronary artery disease or a major cardiovascular event (e.g., myocardial infarction) in the past 6 months; severe uncontrolled arrhythmias; history of complete heart block; significant QTc prolongation (≥450 milliseconds for men and ≥470 milliseconds for women); history of untreated angle-closure glaucoma, or history of angle-closure glaucoma that is considered treated by an ophthalmologist; Montreal Cognitive Assessment (MoCA) <21; congestive heart failure (New York Heart Association [New York Heart Association [New York Heart Association [New York Heart Association [New York Heart Association [New York Heart Association [New York Heart Association [New York Heart Association [New York Heart Association any malignancy other than cervical carcinoma in situ or basal cell carcinoma within 2 years prior to treatment; known gastrointestinal (GI) conditions; psychiatric, neurologic, or behavioral disorders that may interfere with cognition; clinically significant abnormal laboratory findings (e.g., alanine aminotransferase [ALT] or aspartate aminotransferase [AST] ≥3.0 × upper limit of normal [ULN], blood bilirubin [total] ≥3.0 × ULN, estimated glomerular filtration rate (eGFR) <30 mL / min / 1.73 m 2 , or any abnormal laboratory value that may interfere with the safety of the individual).
[0137] In some embodiments, before long-term administration (e.g., 8 weeks or longer) of aproxetine, individuals or patients who respond to aproxetine or can be treated with aproxetine can be first identified for more efficient and effective treatment. For example, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg of aproxetine can be administered to an individual or patient for at least 8 weeks. If the individual or patient responds to aproxetine, the patient or individual may show an improvement in nOH symptoms, which can be demonstrated by a decrease in one or more of the following relative to baseline: Orthostatic Hypotension Symptom Assessment (OHSA) 1, 2, 3, 4, 5, 6 items and comprehensive scores, Orthostatic Hypotension Daily Activities Scale (OHDAS) 1, 2, 3, 4 items and comprehensive scores, Orthostatic Hypotension Questionnaire (OHQ) comprehensive scores. In some embodiments, the reduction in OHSA (comprehensive or any single item), OHDAS (comprehensive or any single item) or OHQ comprehensive scores may be at least 1, 2, 3 or 4 points. For example, administration for at least 8 weeks can reduce the orthostatic hypotension symptom assessment (OHSA) question 1 score ("dizziness, lightheadedness, feeling faint or feeling like you might pass out") by at least 1 or 2 points. If it is determined that the individual or patient is responding to aproxetine, treatment can be continued, and the pharmaceutical composition comprising aproxetine can be administered to the individual or patient for a long term (at least 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 1 year, 2 years, or 3 years). If it is determined that the individual or patient is not responding to aproxetine, treatment can be discontinued and the pharmaceutical composition is no longer administered.
[0138] Example
[0139] Embodiment 1. A method for treating symptomatic neurogenic orthostatic hypotension in a subject with multiple system atrophy, the method comprising administering to the subject daily for at least about 22 weeks a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof, wherein:
[0140] (a) the individual being treated experiences symptoms of neurogenic orthostatic hypotension in the absence of treatment with the pharmaceutical composition, as determined using the Orthostatic Hypotension Assessment Scale (OHSA); and
[0141] (b) daily administration of the pharmaceutical composition to the subject for at least about 22 weeks causes a measurable decrease in both: (i) the subject's symptoms of dizziness, lightheadedness, feeling faint, or feeling like they might pass out as determined using the subject's OHSA Question 1 score; and (ii) the subject's Global Impression of Symptom Severity as determined using the subject's OHSA Composite Score.
[0142] Embodiment 2. The method of embodiment 1, wherein daily administration of the pharmaceutical composition for at least about 22 weeks further results in a measurable decrease in the subject's Orthostatic Hypotension Daily Activities Scale (OHDAS) composite score.
[0143] Embodiment 3. The method of embodiment 1 or 2, wherein daily administration of the pharmaceutical composition for at least about 22 weeks further results in a measurable increase in systolic blood pressure of the subject after standing for 3 minutes.
[0144] Embodiment 4. The method of any one of embodiments 1 to 3, wherein the pharmaceutical composition is administered to the subject orally.
[0145] Embodiment 5. The method of any one of embodiments 1 to 4, wherein the pharmaceutical composition is administered to the subject once daily.
[0146] Embodiment 6. The method of any one of embodiments 1 to 5, wherein prior to administration of the pharmaceutical composition, the subject has a supine plasma norepinephrine level of less than about 200 pg / mL.
[0147] Embodiment 7. The method of any one of embodiments 1 to 6, wherein prior to treatment with the pharmaceutical composition, the subject has a supine plasma norepinephrine level of less than about 350 pg / mL.
[0148] Embodiment 8. The method of any one of embodiments 1 to 7, wherein after about 8 weeks of treatment with the pharmaceutical composition, the subject has a supine plasma norepinephrine level above about 500 pg / mL.
[0149] Embodiment 9. The method of any one of embodiments 1 to 8, wherein aproxetine is administered in the form of a hydrochloride salt.
[0150] Embodiment 10. The method of any one of embodiments 1 to 9, wherein aproxetine is administered as a crystalline hydrochloride salt characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 4.44±0.2, 10.22±0.2, and 21.78±0.2.
[0151] Embodiment 11. The method of embodiment 10, wherein the crystalline aproxetine hydrochloride is further characterized by having one or more additional diffraction peaks at 2θ values selected from 8.11±0.2, 13.18±0.2, 16.06±0.2, 17.16±0.2, 18.38±0.2, 23.76±0.2, 26.32±0.2, 27.24±0.2, 29.60±0.2 and 31.94±0.2.
[0152] Embodiment 12. The method of any one of embodiments 1 to 11, wherein aproxetine is administered as a crystalline hydrochloride salt characterized by a differential scanning calorimetry trace with a melting point of about 197 ± 2 °C.
[0153] Embodiment 13. The method according to any one of embodiments 1 to 12, wherein the pharmaceutically acceptable carrier comprises microcrystalline cellulose.
[0154] Embodiment 14. The method of any one of embodiments 1 to 12, wherein the pharmaceutically acceptable carrier comprises lactose.
[0155] Embodiment 15. The method of any one of embodiments 1 to 12, wherein the pharmaceutically acceptable carrier comprises magnesium stearate.
[0156] Embodiment 16. The method of any one of embodiments 1 to 12, wherein the pharmaceutically acceptable carrier comprises microcrystalline cellulose, lactose, and magnesium stearate.
[0157] Embodiment 17. A method for reducing the magnitude of decline in quality of life in an individual with multiple system atrophy, the method comprising administering to the individual daily for at least about 22 weeks a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof, wherein the magnitude of decline in the individual's quality of life is measured using a self-rated health assessment on a vertical analog scale of the individual.
[0158] Embodiment 18. The method of Embodiment 17, wherein the vertical analog scale comprises endpoints labeled "Best Health You Can Imagine" and "Worst Health You Can Imagine."
[0159] Embodiment 19. The method according to embodiment 17 or 18, wherein the vertical analog scale is part of the EQ-5D-5L questionnaire.
[0160] Embodiment 20. The method of any one of embodiments 17 to 19, wherein the pharmaceutical composition is administered to the subject orally.
[0161] Embodiment 21. The method of any one of embodiments 17 to 20, wherein the pharmaceutical composition is administered to the subject once daily.
[0162] Embodiment 22. The method of any one of embodiments 17 to 21, wherein the decline in quality of life of the subject is increased when the pharmaceutical composition is not administered to the subject.
[0163] Embodiment 23. The method of any one of embodiments 17 to 22, wherein the individual being treated experiences symptoms of neurogenic orthostatic hypotension without treatment with the pharmaceutical composition as determined using the Orthostatic Hypotension Assessment Scale (OHSA); and daily administration of the pharmaceutical composition to the individual for at least about 22 weeks causes a measurable decrease in the individual's symptoms of dizziness, lightheadedness, feeling faint, or feeling like they might pass out as determined using the individual's OHSA Question 1 score.
[0164] Embodiment 24. The method of any one of embodiments 17 to 23, wherein the individual being treated develops symptoms of neurogenic orthostatic hypotension without treatment with the pharmaceutical composition as determined using the Orthostatic Hypotension Assessment Scale (OHSA); and daily administration of the pharmaceutical composition to the individual for at least about 22 weeks results in a measurable decrease in the individual's Global Impression of Symptom Severity as determined using the individual's OHSA composite score.
[0165] Embodiment 25. The method of any one of embodiments 17 to 24, wherein the individual treated experiences symptoms of neurogenic orthostatic hypotension without treatment with the pharmaceutical composition as determined using the Orthostatic Hypotension Assessment Scale (OHSA); and daily administration of the pharmaceutical composition for at least about 22 weeks further results in a measurable decrease in the individual's Orthostatic Hypotension Daily Activities Scale (OHDAS) composite score.
[0166] Embodiment 26. The method of any one of embodiments 17 to 26, wherein daily administration of the pharmaceutical composition for at least about 22 weeks further results in a measurable increase in systolic blood pressure of the subject after standing for 3 minutes.
[0167] Embodiment 27. The method of any one of embodiments 17 to 26, wherein prior to administration of the pharmaceutical composition, the subject has a supine plasma norepinephrine level of less than about 200 pg / mL.
[0168] Embodiment 28. The method of any one of embodiments 17 to 30, wherein prior to treatment with the pharmaceutical composition, the subject has a supine plasma norepinephrine level of less than about 350 pg / mL.
[0169] Embodiment 29. The method of any one of embodiments 17 to 28, wherein after about 8 weeks of treatment with the pharmaceutical composition, the subject has a supine plasma norepinephrine level above about 500 pg / mL.
[0170] Embodiment 30. The method of any one of embodiments 17 to 29, wherein aproxetine is administered as a hydrochloride salt.
[0171] Embodiment 31. The method of any one of embodiments 17 to 30, wherein aproxetine is administered as a crystalline hydrochloride salt characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 4.44±0.2, 10.22±0.2, and 21.78±0.2.
[0172] Embodiment 32. The method of embodiment 31, wherein the crystalline aproxetine hydrochloride is further characterized by having one or more additional diffraction peaks at 2θ values selected from 8.11±0.2, 13.18±0.2, 16.06±0.2, 17.16±0.2, 18.38±0.2, 23.76±0.2, 26.32±0.2, 27.24±0.2, 29.60±0.2 and 31.94±0.2.
[0173] Embodiment 33. The method of any one of embodiments 17-32, wherein aproxetine is administered as a crystalline hydrochloride salt characterized by a differential scanning calorimetry trace with a melting point of about 197±2°C.
[0174] Embodiment 34. The method of any one of embodiments 17 to 33, wherein the pharmaceutically acceptable carrier comprises microcrystalline cellulose.
[0175] Embodiment 35. The method of any one of embodiments 17 to 33, wherein the pharmaceutically acceptable carrier comprises lactose.
[0176] Embodiment 36. The method of any one of embodiments 17 to 33, wherein the pharmaceutically acceptable carrier comprises magnesium stearate.
[0177] Embodiment 37. The method of any one of embodiments 17 to 33, wherein the pharmaceutically acceptable carrier comprises microcrystalline cellulose, lactose, and magnesium stearate.
[0178] Embodiment 38. A method for increasing supine plasma norepinephrine levels in a subject having multiple system atrophy, the method comprising administering to the subject daily for at least about 8 weeks a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof, wherein after about 8 weeks of treatment with the pharmaceutical composition, the subject's supine plasma norepinephrine level is above about 500 pg / mL.
[0179] Embodiment 39. The method of embodiment 38, wherein the pharmaceutical composition is administered to the subject orally.
[0180] Embodiment 40. The method of embodiment 37 or 39, wherein the pharmaceutical composition is administered to the subject once daily.
[0181] Embodiment 41. The method of any one of embodiments 37 to 40, wherein prior to administration of the pharmaceutical composition, the subject has a supine plasma norepinephrine level of less than about 200 pg / mL.
[0182] Embodiment 42. The method of any one of embodiments 37 to 41, wherein prior to administration of the pharmaceutical composition, the subject has a supine plasma norepinephrine level of less than about 350 pg / mL.
[0183] Embodiment 43. The method of any one of embodiments 37 or 42, wherein aproxetine is administered as a hydrochloride salt.
[0184] Embodiment 44. The method of any one of embodiments 37 to 43, wherein aproxetine is administered as a crystalline hydrochloride salt characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 4.44±0.2, 10.22±0.2, and 21.78±0.2.
[0185] Embodiment 45. The method of embodiment 44, wherein the crystalline aproxetine hydrochloride is further characterized by having one or more additional diffraction peaks at 2θ values selected from 8.11±0.2, 13.18±0.2, 16.06±0.2, 17.16±0.2, 18.38±0.2, 23.76±0.2, 26.32±0.2, 27.24±0.2, 29.60±0.2 and 31.94±0.2.
[0186] Embodiment 46. The method of any one of embodiments 37 to 45, wherein aproxetine is administered as a crystalline hydrochloride salt characterized by a differential scanning calorimetry trace with a melting point of about 197 ± 2 °C.
[0187] Embodiment 47. The method of any one of embodiments 37 to 46, wherein the pharmaceutically acceptable carrier comprises microcrystalline cellulose.
[0188] Embodiment 48. The method of any one of embodiments 37 to 46, wherein the pharmaceutically acceptable carrier comprises lactose.
[0189] Embodiment 49. The method of any one of embodiments 37 to 46, wherein the pharmaceutically acceptable carrier comprises magnesium stearate.
[0190] Embodiment 50. The method of any one of embodiments 37 to 46, wherein the pharmaceutically acceptable carrier comprises microcrystalline cellulose, lactose, and magnesium stearate.
[0191] Examples
[0192] The following examples are provided to illustrate various aspects and embodiments of the present disclosure and are not intended to limit the scope of the present disclosure unless specifically stated.
[0193] Unless otherwise noted, all reagents, starting materials, and solvents used in the following examples were purchased from commercial suppliers (eg, Sigma-Aldrich, St. Louis, MO, and its affiliates) and used without further purification.
[0194] Unless otherwise stated, the following abbreviations have the following meanings:
[0195] 5-HT 5-hydroxytryptamine (or serotonin)
[0196] AE adverse event
[0197] bHCG beta human chorionic gonadotropin
[0198] BP
[0199] BSA bovine serum albumin
[0200] BSFC-s Family Caregiver Burden Scale-Short Version
[0201] CHO Chinese Hamster Ovary
[0202] COMPASS-31 Composite Autonomic Symptom Score
[0203] Symptoms Score)-31
[0204] C-SSRS Columbia-Suicidality Severity Rating Scale
[0205] DA Dopamine
[0206] DAT dopamine transporter
[0207] DBP Diastolic blood pressure
[0208] DHPG Dihydroxyphenyl glycol
[0209] DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders
[0210] Manual of Mental Disorders), 4th edition, text revised
[0211] ECG Electrocardiogram
[0212] eGFR estimated glomerular filtration rate
[0213] ESC Enrollment Steering Committee
[0214] ET Early naming
[0215] EQ-5D-5L EuroQol-5D-5L
[0216] FAS Full Analysis Set
[0217] GDPR General Data Protection Regulation
[0218] HADS Hospital Anxiety and Depression Scale
[0219] hDAT human dopamine transporter
[0220] HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid
[0221] Hgba1c Hemoglobin A1c
[0222] HIPAA Health Insurance Portability and Accountability Act
[0223] hNET human norepinephrine transporter
[0224] hSERT human serotonin transporter
[0225] HR
[0226] MAO-I Monoamine oxidase inhibitors
[0227] MAP mean arterial blood pressure
[0228] MAR Missing at Random
[0229] MMRM Repeated Measures Mixed Model
[0230] MoCA Montreal Cognitive Assessment
[0231] MSA Multiple System Atrophy
[0232] MSA-C MSA cerebellar subtype
[0233] MSA-P MSA Parkinson's disease subtype
[0234] NA Norepinephrine
[0235] NE Norepinephrine
[0236] NET norepinephrine transporter
[0237] NF National Formulary Level
[0238] NMSS Non-Motor Symptom Scale
[0239] nOH neurogenic orthostatic hypotension
[0240] NRI Norepinephrine reuptake inhibitor
[0241] NYHA New York Heart Association
[0242] OH Orthostatic hypotension
[0243] OHQ Orthostatic Hypotension Questionnaire
[0244] OHDAS Orthostatic Hypotension Activities of Daily Living Scale
[0245] OHSA Orthostatic Hypotension Symptom Assessment
[0246] OHSA #1 Orthostatic Hypotension Symptom Assessment Question 1
[0247] OL Open label
[0248] PAF Pure autonomic failure
[0249] PBO Placebo
[0250] PD Parkinson's disease
[0251] PDQ-8 Parkinson's Disease Questionnaire-8
[0252] PGI-C Patient Global Impression of Change
[0253] PGI-S Patient Global Impression of Severity
[0254] PI Principal Investigator
[0255] PK Pharmacokinetics
[0256] QD Daily
[0257] RR Respiratory rate
[0258] SAP Statistical Analysis Program
[0259] SBP Systolic blood pressure
[0260] SERT serotonin reuptake transporter
[0261] Symptomatic nOH Symptomatic neurogenic orthostatic hypotension
[0262] SNRI serotonin norepinephrine reuptake inhibitor
[0263] Tris(hydroxymethyl)aminomethane
[0264] ULN Upper limit of normal
[0265] UMSARS Unified Multiple System Atrophy Rating Scale
[0266] UPDRS Unified Parkinson's Disease Rating Scale
[0267] V1, V2, V3 and other study visits
[0268] Other abbreviations used herein but not defined have their ordinary meanings as understood by one of ordinary skill in the art to which they belong.
[0269] Example 1
[0270] Radioligand binding and neurotransmitter uptake assays
[0271] The in vitro pharmacology of aproxetine at human recombinant monoamine transporter and rat native monoamine transporter was characterized as described in Smith et al., International Journal of Neuropsychopharmacology (2015) 1-11 and Tsuruda et al., Journal of Pharmacology and Toxicology Methods (2010) 61: 192-204. See also, for example, U.S. Patent Nos. 8,304,432B2 and 8,304,433B2. Radioligands were from commercial sources (Perkin Elmer Life Sciences or GE Healthcare Life Sciences).
[0272] Briefly, membranes prepared from HEK293 (human embryonic kidney 293) or CHO-K1 (Chinese hamster ovary-K1) cells stably transfected with human recombinant SERT (HEK293-hSERT), NET (HEK293-hNET), or DAT (CHO-K1-hDAT) were incubated in the absence or presence of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine and [ 3 H]-citalopram (1.0 nM) (for SERT), [ 3 H]-nisoxetine (2.0 nM) (for NET) and [ 3 In the case of [H]-WIN35428 (3.0 nM) (for DAT), the cells were incubated in 50 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 0.025% BSA, 100 μM ascorbic acid (pH 7.4) at 22°C for 1 hour. 3 H]-citalopram (2.0 nM) (for SERT) or [ 3 H]-nisoxetine (4.0 nM) (for NET) was incubated for 1 hour at 22°C. For the neurotransmitter uptake assay, HEK293-hSERT, hNET or hDAT cells were pre-incubated in 7.5 mM HEPES, 12.5 mM Tris-HCl, 2.2 mM sodium phosphate, 120 mM NaCl, 5 mM KCl, 0.4 mM MgCl2, 7.5 mM glucose, 1.7 mM CaCl2, 250 μM ascorbic acid, 150 μM pargyline, 0.025% BSA (pH 7.4) at 37°C for 30 minutes in the absence or presence of aproxetine, respectively. 3 H]-5-HT (20 nM), [ 3H]-NE (40 nM) or [ 3 H]-DA (100 nM) for 10 min. 3 H]-5-HT or [ 3 H]-NE for 6 min, and striatal synaptosomes were incubated with [ 3 H]-DA were incubated for 6 min. Binding and uptake analysis were terminated by rapid filtration and radioactivity was measured by liquid scintillation spectrometry. The final [ 3 H]-neurotransmitter concentrations are significantly lower than the corresponding K m , so pIC 50 Close to functional pK i The selectivity for NET is determined as follows (rounded to one significant figure):
[0273] Selectivity = 10 (NET处的pKi或pIC50减去SERT或DAT处的pKi或pIC50) .
[0274] As shown in Table 1 , the in vitro pharmacological profiles of aproxetine at human and rodent monoamine transporters are similar.
[0275] Table 1
[0276] In vitro pharmacology at human recombinant and rat native SERT, NET, and DAT transporters
[0277]
[0278] Data are expressed as mean pIC 50 (Negative decadic IC 50 ) and pK i (Negative decimal logarithm K i ) values. Data represent the mean of 3 to 9 separate experiments (95% confidence intervals in brackets). ND = not determined.
[0279] The data in Table 2 show that aproxetine is a potent inhibitor of NET and SERT, but not DAT, with a 4-fold greater potency for NET than for SERT. Similarly, aproxetine is a potent inhibitor of synaptosomal uptake of [ 3 H]-NE and [ 3 Aproxetine is a potent inhibitor of [H]-5-HT with significant functional selectivity for NET over SERT (10-fold), similar to observations at the human transporter. Consistent with the functional inhibition studies, aproxetine exhibited high binding affinity to human NET and SERT, but not to DAT (Table 2). Apparent binding affinity values for rat native NET and SERT in membranes prepared from rat cortex were similar to those at the human transporter (confidence intervals overlapped), consistent with the lack of species dependence (Table 2).
[0280] Example 2
[0281] In vitro transporter occupancy studies
[0282] Adult male Sprague Dawley rats (Charles River) were housed under controlled laboratory conditions (temperature 21 ± 1 °C) with a 12:12 hour light-dark cycle. Animals had free access to food and water upon arrival at the facility, and were acclimated to their housing room for at least 48 hours. Animals were fasted 15 to 18 hours prior to dosing but had free access to water.
[0283] Rats (n=6 / time point / dose level) received a single oral dose of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine (0.3, 1, 5, 10, 30 and 60 mg / kg) and were euthanized by decapitation at designated time points after dosing (0.5, 2, 4, 6 and 8 hours for the 5 mg / kg dose level; 2 hours for the 0.3, 1, 10, 30 and 60 mg / kg dose levels). Spinal cords from the same animals were dissected for ex vivo transporter occupancy and PK assessments. Spinal cords were obtained by hydraulic compression using phosphate-buffered saline, and lumbar segments were dissected and frozen on dry ice. The remaining spinal cord segments were collected and homogenized in water (25% w / w) for PK analysis. All samples were stored at -80°C until analysis.
[0284] The NET and SERT occupancy in the rat spinal cord was determined using a kinetic radioligand binding assay as previously described in Bourdet et al., J. Pharm. Exp. Ther. (2012) 341: 137-145. PK / PD parameters were estimated by a compartmental modeling approach (WinNonlin version 5.0.1, Pharsight). Single-compartment and dual-compartment PK models with primary absorption and elimination were evaluated. A single-compartment model was selected. The pharmacodynamic model was an effect compartment E directly connected to the central PK compartment. max Models (WinNonlin PK Model 3, PD Model 101). Model selection was based on the best fit in terms of visual inspection, Akaike Information Criteria, and weighted residual sum of squares using Gauss-Newton minimization method. The following parameters were estimated:
[0285] k01(hr -1 ): first-order absorption rate constant.
[0286] V / F(L / kg): Central compartment volume divided by oral bioavailability
[0287] k10(hr -1 ): central compartment elimination rate constant
[0288] E max (Occupancy %): Maximum SERT or NET occupancy in the spinal cord
[0289] EC 50 (ng / mL): Plasma 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine concentration associated with 50% SERT or NET occupancy
[0290] k eo (hr -1 ): first-order equilibrium rate constant between the central pharmacokinetic compartment and the pharmacodynamic effect compartment
[0291] The PK and PD parameter estimates obtained from the effect compartment PK / PD analysis for NET and SERT occupancy are shown in Table 2.
[0292] Table 2
[0293] Pharmacokinetics and occupancy of norepinephrine and serotonin transporters of aproxetine in the rat spinal cord Pharmacodynamic parameter estimates
[0294] parameter SERT NET <![CDATA[E max (% share)]]> 79.0(53) 92.0(19) <![CDATA[EC 50 (ng / mL)]]> 50.8(87) 11.7(6.8) <![CDATA[k eo (hr -1 )]]> 11.0(86) 1.78(57) <![CDATA[k01(hr -1 )]]> 0.777(108) <![CDATA[k10(hr -1 )]]> 0.319(81) V / F(L / kg) 54.8(66)
[0295] *Final parameter estimates are listed with coefficient of variation (CV %) provided in parentheses.
[0296] As shown in Table 2, in rat spinal cord, NET occupancy in EC 50 The estimated value is 11.7 ng / mL, and the EC of SERT occupancy is 50 The estimated value is 50.8 ng / mL. Taking into account the species difference in plasma protein binding (90.2% and 79.1% in rats and humans, respectively), the estimated human plasma EC of NET is 50 The estimated human plasma EC value of SERT is 5.5 ng / mL. 50 The value is 23.9ng / mL.
[0297] Example 3
[0298] Cardiovascular Model in Anesthetized Rats
[0299] These studies were performed to evaluate the effects of a single administration of aproxetine on heart rate (HR) and mean arterial blood pressure (MAP) in anesthetized rats. Using this cardiovascular model, intrinsic effects on HR and inhibition of the pressor response to tyramine were evaluated as surrogate measures of aproxetine's ability to inhibit peripheral norepinephrine transporters.
[0300] A. Experimental design
[0301] Normal blood pressure male Sporged rats weighing between 250-350g were anesthetized by intraperitoneal injection (IP) of thiobutyral (Inactin). During surgery and research, all animals were in a state of complete anesthesia (i.e., no reaction to the toe pinch test). The right common carotid artery and jugular vein were separated and catheterized. During the study, the trachea was intubated to keep the airway open. After the operation was completed, the arterial catheter was connected to a pressure transducer, and the Notocord-HEM data acquisition system was used to record baseline blood pressure [systolic blood pressure (SBP), mean arterial blood pressure (MAP) and diastolic blood pressure (DBP)] and heart rate (HR). After at least 60 minutes at baseline (i.e., the last 10 minutes were stable), vehicle (10% Tween20, 2mL / kg, IP) was administered, and any potential effects were monitored for at least 10 minutes. After this period, the rats were injected with vehicle or aproxetine (0.01-30 mg / mL, 2 mL / kg, IP), and the changes in MAP and HR were monitored for 25 minutes. The rats were then stimulated by intravenous injection via the jugular catheter, and a non-cumulative bolus dose of tyramine (0.03, 0.1, 0.3 and 1 mg / kg, 1 mL / kg, IV) was given every 5 minutes. After the last dose of tyramine, data acquisition was continued for 10 minutes, and then the experiment was terminated. In a separate group of animals, blood was collected 15 minutes and 60 minutes after administration to assess the aproxetine concentration in plasma. The free plasma concentration obtained at 15 minutes was used to construct a concentration response curve (CRC) for MAP and HR, while the concentration obtained at 60 minutes was used to construct a tyramine CRC. The animals were euthanized by carbon dioxide asphyxiation, followed by thoracotomy.
[0302] B. Data analysis
[0303] Intrinsic hemodynamic effects are reported as the maximum change in MAP or HR caused by aproxetine before tyramine stimulation. The inhibition of tyramine effects was normalized to the response to a 1 mg / kg dose of tyramine in the vehicle control group. Concentration response curves (CRC) for changes in MAP, HR, and inhibition of tyramine responses were analyzed using Prism 5.00TM (GraphPad, Inc.) by iterative curve fitting logistic equations. The formula used is as follows:
[0304] Y = (Bottom + Top - Bottom) / (1 + 10^((LogEC50-X)*slope))
[0305] where X is the logarithm of the dose and Y is the response, with Y starting at the bottom (all constrained to 0) and reaching the top in an S-shape. When the change in MAP or HR decreases at higher doses, a more accurate estimate of the top (i.e., maximum efficacy) is obtained by carrying over the maximum effect occurring at the lower dose to all subsequent higher doses. For tyramine CRC, the top was constrained to 100. The potency of the pressor effect is reported as MAP PC 10 , which is the free plasma concentration that causes a 10 mm Hg change in MAP, and the potency of the HR effect is reported as HR PC 25 , which is the free plasma concentration that causes a 25 bpm change in HR. Finally, the potency to inhibit the effects of tyramine is reported as TyrEC 50 , which is the concentration that produces 50% inhibition of the SBP increase induced by tyramine (1 mg / kg, IV).
[0306] Using this formula, the inhibitory potency (pIC) obtained by measuring the inhibition of labeled 5-HT uptake by rat serotonin transporter (rSERT) in rat cortical synaptosomes is converted to 50 value) into IC 50 value:
[0307] Y=(10^(-x))×(10^9)
[0308] C. result
[0309] Aproxetine (0.01-30 mg / kg, IP) dose-dependently increased MAP and HR in anesthetized rats. When the corresponding free plasma concentrations were plotted for each dose, the estimated MAP and HR potency was 101.4 nM (MAP EC 10 ) and 8.6 nM (HREC 25 ). The maximum changes in MAP and HR were 13.2 (4.4-22.1) mm Hg and 28.1 (22.4-33.7) bpm, respectively. Aproxetine also inhibited the tyramine-induced increase in SBP. When expressed as % inhibition of the response to 1 mg / kg tyramine administered intravenously, the estimated potency of aproxetine was 0.86 nM.
[0310] D. in conclusion
[0311] In a cardiovascular model in anesthetized rats, aproxetine demonstrated potent inhibition of the tyramine pressor response and tachycardia, consistent with NET inhibition in the periphery.
[0312] Example 4
[0313] Preparation of oral administration solution
[0314] Aproxetine hydrochloride solutions for oral administration were prepared in two steps: First, a 3 mg / mL aqueous stock solution was prepared, and then oral solutions of different dosage strengths were prepared in filtered apple juice prior to administration.
[0315] A. Preparation of stock solutions
[0316] Aproxetine hydrochloride (500 mg, 89.9% purity) was added to a 250 mL clear glass bottle. Sterile water for injection (150 mL) was added and the bottle was capped. The bottle was gently swirled in a circular motion until no solid matter was observed (approximately 20 minutes). The bottle may also be sonicated if necessary. The bottle was labeled and the stock solution (3 mg / mL) was used within 2 hours or stored in a refrigerator at 2 to 8° C. until use. Any stock solution not used within 6 days of initial preparation was discarded.
[0317] B. Preparation of oral administration solution
[0318] Oral dosing solutions with seven different dosage strengths were prepared for use in Part A or Part B of the clinical study. The dosage strengths prepared and the amounts used to prepare each dosage strength are shown in Tables 3 and 4:
[0319] Table 3 Solution for oral administration (Part A)
[0320]
[0321] Table 4 Solution for oral administration (Part B)
[0322]
[0323] To prepare the oral dosing solution, remove the stock solution (3 mg / mL) from the refrigerator and visually inspect for precipitation. If precipitation is present, prepare a fresh stock solution.
[0324] Apple juice (at least 40 mL, Mott's 100% original apple juice) was drawn into a 50 mL syringe and a syringe filter (25 mm PVDF syringe filter, 0.2 μm, Pall Life Sciences) was connected to the syringe. The apple juice was filtered through the syringe filter, the first 3 mL was discarded, and the remaining apple juice was collected in a 125 mL amber bottle.
[0325] The stock solution (3 mg / mL) in the amount (stock solution volume) shown in Table 3 or Table 4 was then added to a new 125 mL amber bottle, and the corresponding amount (apple juice volume) of filtered apple juice shown in Table 3 or Table 4 was added to the bottle. The bottle was capped and the contents were mixed by swirling in a circular motion for more than 2 minutes. The resulting solution was stored at ambient room temperature for up to 18 hours prior to dosing to a subject. Prior to dosing to a subject, a 10 mL aliquot of the oral solution was transferred to a new 125 mL amber bottle.
[0326] Example 5
[0327] Preparation of oral tablets for Phase 3 studies
[0328] Microcrystalline cellulose (35.32 kg; AVICEL microcrystalline cellulose, NF, European Pharmacopoeia type PH-112) and anhydrous lactose (21.00 kg; anhydrous 60M, NF, EP) were charged into a blending box and blended at 20 rpm for 5 minutes. The resulting mixture was transferred to a double polyethylene (PE) lined container ("Premix 1") and divided into two portions, one portion weighing approximately 10 kg ("Premix 1A") and another portion containing the remainder ("Premix 1B"). About half of Premix 1A was added to the box, followed by aproxetine monohydrochloride (3.382 kg; ground), followed by the other half of Premix 1A. The resulting mixture was blended at 20 rpm for 10 minutes and then transferred to a double PE lined container ("Active Premix 2"). About half of Premix 1B was passed through a grinder equipped with a 1.0 mm screen at 1000 rpm (800-1200 rpm), impinged forward, followed by the addition of Active Premix 2, followed by the other half of Premix 1B. The ground material was collected into a double PE lined container ("ground premix 3"). The ground premix 3 was passed through a 40 mesh screen, and the sieved material was transferred to a blending box and blended at 20 rpm for 25 minutes ("premix 4"). Two full spoons of premix 4 were taken out and manually mixed with magnesium stearate (300.0 g, NF) in a polyethylene bag. This mixture was then passed through a 40 mesh handheld screen. The sieved mixture was then added back into the blending box, and the entire mixture was blended at 20 rpm for 5 minutes ("final blend"). The final blend was compressed into 200 mg tablets using a tablet press, and the tablets were passed through a dust collector and a metal detector. Acceptable tablets were collected in a double PE lined container.
[0329] Purified water (12.48 kg, USP) was added to a clean stainless steel solution preparation vessel and the mixer speed was adjusted to form a vortex. A polyvinyl alcohol-based film coating (3.12 kg; OPADRY II White 85G18490, Colorcon, Inc., West Point, PA) was added to the vortex in the mixing tank and the mixing speed was reduced so that there was no more vortex and mixing continued for at least 45 minutes or until the color was visually uniformly dispersed. Gently mix before and during the coating process. The tablets prepared above were placed in a coating pan and the pan speed was set to 6 rpm. The coating solution was pumped into the coating pan. While the coating solution was pumped into the coating pan, the weight change of the coating solution was monitored and the addition of the coating solution was stopped when a 4% increase in tablet dry weight was achieved based on the amount of coating suspension used. The resulting white tablets contained approximately 10 mg of aproxetine (free base equivalent).
[0330] Example 6
[0331] A phase 3, 4-week clinical study in individuals with symptomatic nOH
[0332] This study is a phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of aproxetine (administered as aproxetine hydrochloride) after four weeks of treatment in subjects with primary autonomic failure (MSA, PD, or PAF) and symptomatic nOH. Subjects will participate in the study for approximately 10 weeks.
[0333] A total of 185 individuals completed this study. Individuals were randomly assigned to each of the aproxetine group or placebo group stratified by individual disease type (MSA, PD or PAF) at a 1:1 ratio. 98 individuals were randomly assigned to the aproxetine group (8 individuals withdrew during the study), and 97 individuals were randomly assigned to the placebo group (2 individuals withdrew during the study). 37% of the individuals included in the study suffered from MSA.
[0334] A. Study Group
[0335] Adult individuals with a confirmed diagnosis of symptomatic nOH due to MSA, PD, or PAF who met all inclusion criteria defined in the study protocol and did not meet any exclusion criteria were included in this study.
[0336] 1. Inclusion criteria
[0337] Individuals who met the following criteria were eligible for inclusion in the study.
[0338] (a) The individual is male or female and is at least 30 years old.
[0339] (b) For female subjects only: Subjects are not pregnant and not breastfeeding. Females of childbearing potential must have a documented negative pregnancy test result at screening. Females are considered to be of childbearing potential unless they are postmenopausal (amenorrhea for at least 2 years) or have documented surgical sterilization (bilateral tubal ligation or total hysterectomy). Female subjects are allowed to participate in the study based on a negative urine pregnancy test result. If the urine bHCG (beta human chorionic gonadotropin) test is positive, a serum bHCG test is performed. A negative pregnancy test must be confirmed for an individual to be eligible to participate in this study.
[0340] (c) Females of childbearing potential or males of childbearing potential agree to use highly effective contraceptive measures (failure rate < 1% when used consistently and correctly) or agree to refrain from sexual intercourse during the study and for 30 days after the last dose of study drug.
[0341] (d) The individual met the diagnostic criteria for nOH as evidenced by a sustained decrease in BP of ≥20 mmHg (systolic BP) or ≥10 mmHg (diastolic BP) within 3 minutes of tilting upward ≥60° from the supine position as determined by tilt table testing.
[0342] (e) The individual's score on Orthostatic Hypotension Symptom Assessment Question #1 is at least 4 at the randomization visit.
[0343] (f) For subjects with PD only: Subjects were diagnosed with PD according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank criteria (1992).
[0344] (g) For individuals with MSA only: individuals were diagnosed with possible or probable MSA parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) according to the Gilman criteria (2008).
[0345] (h) For subjects with PAF only: Subjects with documented impaired autonomic reflexes, including the Valsalva maneuver, performed within 24 months of the date of randomization.
[0346] (i) After 30 minutes in a sitting position, the subject's plasma NE level is >100 pg / mL.
[0347] (j) The individual is willing and able to provide signed and dated written informed consent prior to the commencement of any research-related procedures.
[0348] (k) The individual is able to communicate well with the investigators and clinic staff, understands the expectations of the study, and is able to comply with the study procedures, requirements, and limitations.
[0349] 2. Exclusion criteria
[0350] Individuals meeting any of the following criteria were not eligible for inclusion in the study.
[0351] (a) The individual has a known systemic disease known to produce autonomic neuropathy, including but not limited to amyloidosis and autoimmune neuropathies. The individual has diabetes and a diagnosis of PAF. Individuals with diabetes and MSA or PD are evaluated on a case-by-case basis by a medical monitor and are considered ineligible unless all of the following criteria are met:
[0352] i. Type 2 DM can be well controlled with oral medications and diet alone;
[0353] ii. HgbA1C ≤7.5% during the screening period or up to 12 weeks prior to screening;
[0354] iii. No clinically apparent peripheral neuropathy (e.g., normal sensory examination of the limbs);
[0355] iv. No known retinal disease (e.g., annual eye examinations are sufficient); and
[0356] v. No renal disease (eg, no albuminuria and GFR>60).
[0357] (b) The individual is known to be intolerant to other NRIs or serotonin norepinephrine reuptake inhibitors (SNRIs).
[0358] (c) The subject is concomitantly using an antihypertensive agent for the treatment of essential hypertension.
[0359] (d) The individual has used a strong CYP1A2 inhibitor or inducer within 7 days or 5 half-lives (whichever is longer) before randomization, or requires concomitant use before the follow-up visit.
[0360] (e) The subject has changed the dose, frequency, or type of medication prescribed for the treatment of orthostatic hypotension within 7 days prior to the randomization visit (midodrine and droxidopa (if applicable) must be tapered at least 7 days prior to randomization).
[0361] (f) The individual is known or suspected to have alcohol or drug abuse (DSM- definition).
[0362] (g) The individual has clinically unstable coronary artery disease or has experienced a major cardiovascular or neurological event in the past 6 months.
[0363] (h) The individual had used any monoamine oxidase inhibitor (MAO-I) within 14 days before randomization.
[0364] (i) The individual has a history of untreated angle-closure glaucoma or a history of treated angle-closure glaucoma that the ophthalmologist believes may place the individual at increased risk.
[0365] (j) The subject has any severe uncontrolled cardiac arrhythmia.
[0366] (k) The individual's Montreal Cognitive Assessment (MoCA) ≤ 23.
[0367] (l) The individual is unable or unwilling to complete all procedures specified in the protocol, including questionnaires.
[0368] (m) The individual has had a myocardial infarction within the past 6 months or currently suffers from unstable angina.
[0369] (n) Subjects are known to have congestive heart failure (New York Heart Association [NYHA] class 3 or 4).
[0370] (o) The individual has had any malignant disease other than cervical carcinoma in situ or basal cell carcinoma in the past 2 years before screening.
[0371] (p) Subjects are known to have gastrointestinal (GI) conditions that, at the discretion of the investigator, could affect absorption of the study agent (e.g., ulcerative colitis, gastric bypass surgery).
[0372] (q) The subject suffers from a mental, neurological or behavioral disorder that may interfere with the subject's ability to give informed consent or with the conduct of the research.
[0373] (r) The individual is currently receiving any investigational drug or has received an investigational drug within 30 days of administration. Investigational drugs are defined as drugs that are not approved by a regulatory agency (e.g., the Food and Drug Administration).
[0374] (s) Individuals with clinically significant abnormal laboratory findings (e.g., alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3.0 × upper limit of normal [ULN]; blood bilirubin [total] >1.5 × ULN; estimated glomerular filtration rate (eGFR) <30 mL / min / 1.73 m 2 ; or any abnormal laboratory value that may interfere with the safety of the individual).
[0375] (t) The individual has demonstrated lifetime suicidal ideation and / or suicidal behavior as outlined by the C-SSRS (baseline / screening version); the assessor should assess the individual's suicide risk and the individual's appropriateness for inclusion in the study.
[0376] (u) The subject has a concurrent disease or condition that, in the opinion of the investigator, would confound or interfere with study participation or the assessment of the safety, tolerability, or pharmacokinetics of the study drug.
[0377] (v) The individual has a known hypersensitivity to aproxetine (aproxetine hydrochloride) or any excipient in the formulation.
[0378] (w) Individuals who (i) have confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with a documented positive coronavirus disease 2019 [COVID-19] test result; or (ii) are suspected of having SARS-CoV-2 infection (no documented test result for clinical features two weeks after resolution of symptoms and remain asymptomatic as of Day 1); or (iii) have had close contact with a person known (or suspected) to have SARS-CoV-2 infection and remain asymptomatic as of Day 1.
[0379] 3. Prohibitions and Restrictions
[0380] According to regulations, the following contents are prohibited or restricted during participation in the study.
[0381] (a) Subjects must have discontinued concomitant use of strong CYP1A2 inhibitors and inducers for 7 days or 5 half-lives (whichever is longer) prior to randomization. This restriction applies to concomitant medications, herbal supplements (e.g., St John's Wort), and normal dietary intake.
[0382] (b) The use of prescription medications for the treatment of OH other than fludrocortisone is prohibited.
[0383] (c) Alpha-blockers (e.g., Prazosin, Terazosin, Doxazosin, Silodosin, Alfuzosin, Tamsulosin) are contraindicated.
[0384] (d) Norepinephrine reuptake inhibitors (NRIs) (e.g., atomoxetine and reboxetine) and serotonin and norepinephrine reuptake inhibitors (SNRIs) (e.g., duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) are prohibited.
[0385] (e) The use of psychostimulants (e.g., amphetamine, dextroamphetamine, methylphenidate, pemoline) is prohibited.
[0386] (f) Subjects were asked to avoid any major dietary changes throughout the study period. Subjects were reminded to maintain adequate fluid intake during scheduled visits.
[0387] B. Test product, dose and route of administration; regimen; duration of treatment
[0388] Subjects were randomized in a 1:1 ratio to receive either aproxetine (test product) or placebo (reference product) once daily until the end of the treatment period.
[0389] The test product was aproxetine supplied as 10 mg tablets in 35-count high-density polyethylene bottles labeled in a blinded manner (eg, the bottle labels for the test product were indistinguishable from the reference product except for the coded unique bottle number).
[0390] Aproxetine was administered orally at approximately the same time each morning, regardless of food intake, with approximately 8 ounces of water.
[0391] Subjects randomized to receive aproxetine began taking study medication at a dose of 10 mg on the morning of Day 2 and continued taking this dose once daily until the end of the treatment period.
[0392] D. Reference product, dose and route of administration; regimen; duration of treatment
[0393] The reference product was a placebo tablet supplied identical to the test product in excipient content (except aproxetine), appearance, number of tablets, and packaging (e.g., the bottle label of the reference product was indistinguishable from the test product except for the coded unique bottle number).
[0394] Placebo was administered orally at approximately the same time each morning, regardless of food intake, and was taken with approximately 8 ounces of water.
[0395] Subjects randomized to receive placebo began taking study medication on the morning of Day 2 and continued taking placebo once daily until the end of the treatment period.
[0396] E. Study Execution
[0397] For the purposes of this study, symptomatic neurogenic orthostatic hypotension was defined as:
[0398] (a) a sustained decrease in BP of ≥20 mmHg (systolic BP) or ≥10 mmHg (diastolic BP) within 3 minutes of standing or tilting upward ≥60° from a supine position; and
[0399] (b) A score of at least 4 on Orthostatic Hypotension Symptom Assessment Question #1.
[0400] The study consisted of three phases: (i) a 4-week screening period, (ii) a 4-week randomized treatment period, and (iii) a 2-week follow-up period.
[0401] After signing informed consent, subjects entered a 4-week screening period to confirm eligibility. At the screening visit for all subjects in the clinic, subjects provided a complete medical history of their medical conditions and treatments. The subject's medical conditions were described and recorded by the study staff. Subjects underwent an assessment of their physical status, including safety and laboratory assessments. The presence of symptomatic nOH symptoms and reported dizziness, lightheadedness, feeling faint, or feeling like passing out (OHSA#1) was confirmed by the application of a tilt table test. This tilt table test was used for two purposes: (i) to determine systolic / diastolic BP (DBP) changes, and (ii) to train subjects to recognize sensations associated with OHSA#1.
[0402] Eligible individuals were trained to accurately rate the sensations of dizziness, lightheadedness, feeling faint, or feeling like passing out as outlined in OHSA #1.
[0403] After the screening period, individuals continued for a second visit to further confirm other eligibility criteria before random assignment. This visit included completion of the Orthostatic Hypotension Questionnaire (OHQ), which required a minimum score of 4 points on OHSA#1. Individuals who met all applicable inclusion criteria and did not meet any applicable exclusion criteria (including confirmation of relevant criteria by an independent enrollment steering committee (ESC)) were randomly assigned to receive aproxetine or matching placebo for the next 4 weeks.
[0404] Following randomization and completion of study assessments, subjects received a single 10 mg dose of aproxetine (or matching placebo) once daily (QD) for the remainder of the double-blind treatment period.
[0405] Individuals were assessed weekly. Research staff were provided with descriptions of all assessments and detailed instructions for conducting individual assessments in the clinic and remotely. These instructions were provided to ensure that the methodology and implementation of each assessment was consistent across sites and individuals for both clinic and remote visits.
[0406] Subjects may discontinue at any time. Criteria for discontinuation of dosing include meeting at least one of the following conditions.
[0407] (a) The investigator determines that further administration of the investigational agent may pose a safety concern to the subject.
[0408] (b) SBP ≥ 180 mmHg or diastolic BP (DBP) ≥ 110 mmHg continuously (for at least 4 hours) after standing for 3 minutes or sitting for 5 minutes, or SBP ≥ 180 mmHg or DBP ≥ 110 mmHg continuously (for at least 4 hours) measured in the supine position (head / trunk elevated approximately 30° from horizontal position).
[0409] (c) AEs determined by the investigator to be intolerable.
[0410] (d) Individual pregnancy.
[0411] No dose reduction was allowed at any time.
[0412] Safety assessments included physical examination, neurological examination, vital signs (temperature, HR, and BP), weight, ECG, safety laboratory tests (hematology, chemistry, and urinalysis), C-SSRS, and AEs. Safety was reviewed regularly by an independent data monitoring committee.
[0413] Subjects were asked to avoid any major dietary changes throughout the study period. Subjects were reminded to maintain adequate fluid intake during scheduled visits.
[0414] Individuals who completed the 4-week double-blind treatment period were eligible to enroll in a separate follow-up study and continue to receive the study medication. For individuals who did not complete the 4-week double-blind treatment period or chose not to continue to participate in the follow-up study, the final study visit was a follow-up visit (V7). This visit was completed two weeks from the date of the last dose.
[0415] F. Research objectives
[0416] The primary objective of the study was to evaluate the efficacy of aproxetine compared with placebo at week 4 in individuals with multiple system atrophy (MSA), Parkinson's disease (PD), or pure autonomic failure (PAF) experiencing symptomatic neurogenic orthostatic hypotension (symptomatic nOH), as measured by the change from baseline in the Orthostatic Hypotension Symptom Assessment (OHSA) question 1 (OHSA#1) score.
[0417] The secondary objectives of the study are as follows.
[0418] (a) The efficacy of aproxetine was evaluated by symptom and activity assessment using the OHSA and the Orthostatic Hypotension Daily Activities Scale (OHDAS).
[0419] (b) The Patient Global Impression of Change (PGI-C) was used to evaluate the efficacy of aproxetine.
[0420] (c) To assess the efficacy of aproxetine in preventing falls.
[0421] (d) To evaluate the safety and tolerability of aproxetine, including adverse events (AEs) and changes in blood pressure (BP), heart rate (HR), electrocardiogram (ECG), Columbia-Suicide Severity Rating Scale (C-SSRS), and laboratory tests.
[0422] The exploratory objectives of the study are as follows.
[0423] (a) The efficacy of aproxetine was assessed using disease-specific instruments, the Unified Parkinson's Disease Rating Scale (UPDRS), the Parkinson's Disease Questionnaire-8 (PDQ-8), the Unified Multiple System Atrophy Rating Scale (UMSARS), and the Composite Autonomic Symptom Score-31 (COMPASS-31).
[0424] (b) Standing blood pressure during the upright stand test was used to assess the efficacy of aproxetine.
[0425] (c) The generic quality of life assessment EuroQol-5D-5L (EQ-5D-5L) was used to evaluate the efficacy of aproxetine.
[0426] (d) To explore the potential benefits of aproxetine on non-dopaminergic symptoms in individuals with primary autonomic failure.
[0427] (e) Exploring pharmacodynamic markers in individuals with primary autonomic failure.
[0428] (f) Providing information for population PK modeling by collecting sparse PK samples in individuals with primary autonomic failure.
[0429] (g) The Family Caregiver Burden Scale-Short Version (BSFC-s) was used to assess the caregiver burden of caring for individuals with primary autonomic failure.
[0430] G. Research Assessment
[0431] Efficacy assessments for this study included: OHQ; PGI-C; and fall incidence. Exploratory assessments included: Upright Stand Test; PK and pharmacodynamics; Non-Motor Symptom Scale (NMSS); EQ-5D-5L; Hospital Anxiety and Depression Scale (HADS); and Family Caregiver Burden Scale-Short Version (BSFC-s). For individuals with PD, study assessments included: UPDRS and PDQ-8; and for individuals with MSA, study assessments included: COMPASS-31 and UMSARS.
[0432] Safety and tolerability assessments included: physical examination; neurologic examination; vital signs, including gait BP; resting ECG; safety laboratory tests, including chemistry, hematology, and urinalysis; concomitant medications; AEs; individual compliance with study treatment; and C-SSRS.
[0433] For pharmacokinetic assessments, a sparse PK sampling strategy was adopted in this study, in which samples were collected at selected study visits. The time of study dose intake was accurately recorded on the day before and on the day of each study visit when PK samples were collected.
[0434] For pharmacodynamic assessments, blood samples were collected approximately 30 minutes after the subjects were seated for analysis of pharmacodynamic markers (including [dihydroxyphenylglycol] DHPG and NE).
[0435] H. Statistical methods
[0436] 1. Sample size
[0437] The study was designed to have a sample size of approximately 188 individuals in total, who were randomly assigned in a 1:1 ratio to either aproxetine or placebo stratified by disease type (MSA, PD, or PAF). The study was designed to include at least 40% of individuals with MSA (i.e., at least 76 individuals with MSA in total).
[0438] The full analysis set (FAS) was defined as all randomized individuals who received at least 1 dose of study medication and had baseline and at least 1 post-baseline OHSA#1 measurement. The primary analysis was performed when all individuals in the FAS had completed the primary endpoint assessment (OHSA#1 at Week 4) and the database had been cleaned and locked. Assuming a standard deviation of 3.0 for the two treatment groups at a two-sided alpha level of 0.05, a total sample size of 170 individuals would have an overall power of 90% to detect a 1.5 treatment difference in the primary endpoint of change from baseline in OHSA#1.
[0439] Assuming a 10% dropout rate at Week 4, the study is expected to randomize approximately 188 individuals in order to reach 170 individuals in the FAS.
[0440] 2. Study End Points
[0441] The primary study endpoint was the change from baseline in OHSA#1 (dizziness, lightheadedness, feeling faint, or feeling like passing out) at Week 4.
[0442] Secondary endpoints were:
[0443] ●Change from baseline in OHSA composite score from Weeks 1 to 4;
[0444] ●Change from baseline in OHDAS composite score from Weeks 1 to 4;
[0445] PGI-C at week 4; and
[0446] ●Fall incidence.
[0447] Exploratory endpoints for all individuals were:
[0448] ●Standing systolic blood pressure during the upright standing test;
[0449] ●Change from baseline in OHSA #1 at Weeks 1 to 3;
[0450] ●Change from baseline in OHSA questions 2 to 6 at weeks 1 to 4;
[0451] ●Change from baseline in OHDAS questions 1 to 4 at weeks 1 to 4;
[0452] ●Change from baseline in the OHQ global composite score at weeks 1 to 4;
[0453] ●Change from baseline in OHDAS questions 1 and 2 at weeks 1 to 4;
[0454] Change from baseline in EQ-5D-5L at week 4;
[0455] PK and pharmacodynamics;
[0456] Non-Motor Symptom Scale (NMSS);
[0457] Hospital Anxiety and Depression Scale (HADS); and
[0458] ●Family Caregiver Burden Scale-Short Version (BSFC-s).
[0459] Exploratory endpoints for individuals with PD are:
[0460] Change from baseline in UPDRS at Week 4; and
[0461] ●Change from baseline in PDQ-8 at Week 4.
[0462] Exploratory endpoints for individuals with MSA were:
[0463] Change from baseline in COMPASS-31 at Week 4; and
[0464] ●Change in UMSARS from baseline at Week 4.
[0465] Safety and tolerability endpoints included:
[0466] ●Physical examination;
[0467] Neurological examination
[0468] ● Vital signs, including gait and BP;
[0469] ● ECG while lying down
[0470] ●Clinical laboratory tests, including biochemistry, hematology, and urinalysis;
[0471] ● Concomitant medication;
[0472] ●AE;
[0473] The individual's compliance with study treatment; and
[0474] ●C-SSRS.
[0475] 3. End point analysis
[0476] The analysis based on FAS is based on the randomized treatment assigned. The safety analysis set is defined as all randomized individuals who have received at least one dose of study medication, and the individuals are analyzed according to the actual study treatment received by the individuals. Unless otherwise specified, all data are summarized by treatment group. Descriptive statistics are used to present continuous variables. Categorical variables are summarized using individual counts and individual percentages in the corresponding categories.
[0477] The primary efficacy assessment was the change from baseline in OHSA#1 at Week 4. Baseline was defined as the pre-dose measurement on Day 1. A repeated measures mixed model (MMRM) was fitted to compare treatments. The model included the following fixed effect categorical terms: treatment, baseline disease type (MSA, PD, PAF), week, and baseline OHSA#1 score as a continuous covariate, random individual effects, and an unstructured covariance structure using the FAS.
[0478] Least squares means and 95% confidence intervals for the differences between aproxetine and placebo were calculated. Missing data in the MMRM analysis were assumed to be missing at random (MAR) and were not imputed for the analysis of the primary endpoint. Sensitivity analyses of the primary endpoint were performed using multiple imputation. The primary analysis was repeated for a set of prespecified subgroups and presented in graphical format.
[0479] The following secondary efficacy endpoints were tested by a statistical testing procedure that protected the family-wise Type I error rate at a two-sided significance level of 5% until the null hypothesis could not be rejected:
[0480] ●Change from baseline in OHSA composite score at week 4;
[0481] ●Change from baseline in OHDAS composite score at week 4;
[0482] PGI-C at week 4; and
[0483] ●Fall incidence at week 4.
[0484] After failing to reject the null hypothesis, it is not statistically significant.
[0485] The following secondary efficacy endpoints were analyzed in a similar manner as the primary efficacy endpoint of change from baseline in OHSA #1, including assessments of, for example, change from baseline in the OHSA composite score and the OHDAS composite score.
[0486] The PGI-C was summarized as the number and percentage of individuals who were “improved” and “no change or worsening” at week 4. The incidence of falls was summarized as the number and percentage of individuals who had at least one fall at week 4. These endpoints were tested with the use of the Cochran-Mantel-Haenszel chi-square test, stratified by disease type at baseline.
[0487] Nominal p values and 95% confidence intervals without adjustment for multiplicity are provided for all supporting analyses, including sensitivity analyses of the primary efficacy end point and exploratory end points.
[0488] Safety data were presented by topic and summarized using event frequencies or descriptive summary statistics as appropriate. Summary tables of physical examinations, neurological examinations, vital signs (temperature, HR, and BP), weight, ECG, safety laboratory tests (hematology, chemistry, and urinalysis), C-SSRS, AEs, and concomitant medications were prepared.
[0489] I. Study Results
[0490] The study did not meet its primary endpoint. There was no statistically significant change from baseline in the Orthostatic Hypotension Symptom Assessment (OHSA) Question 1 (OHSA#1) scores at Week 4 in subjects receiving aproxetine compared with subjects receiving placebo. Most treatment-related adverse events were mild or moderate in severity. Two subjects taking placebo and four subjects taking aproxetine experienced serious adverse events, but none were considered related to study medication; no deaths were reported. There were no signals for supine hypertension.
[0491] However, it is also shown that at week 4, the total anxiety score of individuals with MSA who were administered aproxetine was reduced relative to baseline, indicating that aproxetine is effective for anxiety caused by nOH. Table 5 shows the change in the total anxiety score of MSA individuals at week 4 relative to baseline. The total anxiety score was determined using standard procedures (see, e.g., Rishi et al., Hospital Anxiety and Depression Scale Assessment of 100 Patients Before and After Using Low Vision Care: A Prospective Study in a Tertiary Eye Care Setting, Indian J Ophthalmol, November 2017; 65(11): 1203-1208).
[0492] Table 5
[0493]
[0494] Example 7
[0495] Phase 3, 22-week clinical study in individuals with symptomatic nOH
[0496] This is a Phase 3, multicenter, randomized discontinuation study to evaluate the sustained benefit of aproxetine (administered as aproxetine hydrochloride) in efficacy and safety after 22 weeks of treatment in subjects with primary autonomic failure (MSA, PD, or PAF) and symptomatic nOH. Eligible subjects were (i) completers of the Example 6 study ("Completer Group"), or (ii) symptomatic nOH subjects who met all applicable study inclusion criteria and did not meet any applicable exclusion criteria ("De Novo Group").
[0497] The study consisted of 3 phases: (i) a 16-week open-label (OL) aproxetine treatment period, (ii) a 6-week randomized placebo-controlled treatment period, and (iii) a 2-week follow-up (only for subjects not included in the continuation study 0171). The 4-week screening period was applied only to the treatment-naive group, and all treatment-naive subjects underwent a screening visit in the clinic.
[0498] A total of 203 subjects entered this study (170 subjects from Example 6 (85 from the aproxetine group and 85 from the placebo group) and 33 treatment-naive subjects). In the OL period, 55 subjects discontinued treatment. At 16 weeks, 64 subjects were randomized to the aproxetine group (6 subjects discontinued the study), and 64 subjects were randomized to the placebo group (3 subjects discontinued the study). A total of 119 subjects completed the study. Of the 128 subjects who entered the randomization period, 40 subjects had MSA (31%); 68 subjects had PD (53%); and 20 subjects had PAF (16%) (within each category, subjects were evenly distributed between aproxetine and placebo).
[0499] A. Study Group
[0500] Adult individuals with a confirmed diagnosis of symptomatic nOH due to MSA, PD, or PAF who met all inclusion criteria defined in the study protocol and did not meet any exclusion criteria were included in this study.
[0501] 1. Individuals entering from the finisher group
[0502] After signing the informed consent form, the subject entered Visit 1 (V1), which was conducted on the same day as Visit 6 (V6 / D29) of Example 6. The visit mode (per subject clinic visit or remote visit) for a given subject in this example was consistent with the mode selected by the subject in Example 6. The Example 6 procedures performed at V6 served as the baseline assessment for V1 of this example.
[0503] Beginning on day 2, subjects received a single dose of 10 mg aproxetine once daily (QD) and continued for a 16-week OL treatment period thereafter. Following this 16-week OL treatment period, subjects were randomized to continue active treatment or receive placebo ("PBO") for a 6-week period.
[0504] 2. Individuals in the treatment-naive group
[0505] Eligible individuals were trained to accurately rate dizziness, lightheadedness, feeling faint, or feeling like passing out as outlined on the Orthostatic Hypotension Symptom Assessment Question 1 (OHSA#1).
[0506] Following the Screening Period, individuals proceeded to V1 to further confirm additional eligibility criteria before proceeding. This included completion of the Orthostatic Hypotension Questionnaire (OHQ), with a minimum score of 4 on OHSA#1 required.
[0507] Subjects who met all inclusion criteria, did not meet any exclusion criteria, and whose disease characteristics were confirmed by an independent enrollment steering committee (ESC) received aproxetine during the OL phase.
[0508] Beginning on day 2, subjects received a single dose of 10 mg aproxetine once daily (QD) and continued on for a 16-week OL treatment period thereafter. Following this 16-week OL treatment period, subjects were randomized to continue active treatment or receive PBO for a 6-week period.
[0509] 3. Inclusion criteria
[0510] Completer group individuals who met the following criteria were eligible for inclusion in the study.
[0511] (a) Completed 4 weeks of double-blind treatment in Example 6 (V6) and the investigator determined that the patient would benefit from continued treatment with aproxetine. It is not necessary to achieve a minimum score of OHSA #1 to enter V1.
[0512] (b) In Example 6, the subject's study medication compliance is at least 80%.
[0513] (c) The individual is able to understand the nature of the research and provide written informed consent prior to any research procedures (including understanding that entry into the research may result in changes to the individual's current treatment regimen).
[0514] (d) Subjects are willing to continue treatment regardless of the likelihood of randomization to aproxetine or PBO during the randomized withdrawal period and continue to meet the inclusion criteria of the aforementioned study (Example 6), but inclusion requires tilt table testing, ESC review, and eligibility approval.
[0515] Treatment naive subjects who met the inclusion criteria of Example 6 were eligible for inclusion in this study.
[0516] 4. Exclusion criteria
[0517] Individuals in the completer group who met any of the following criteria were not eligible for study inclusion.
[0518] (a) The subject must not be enrolled in another clinical trial (except Example 6).
[0519] (b) The subject suffers from a mental, neurological, or behavioral disorder that may interfere with the subject's ability to give informed consent or with the conduct of the research.
[0520] (c) Medical, laboratory, or surgical problems that the investigator considers to be of clinical significance.
[0521] (d) An attitude of uncooperativeness or a reasonable likelihood of non-compliance with the plan.
[0522] (e) The subject has a concurrent disease or condition that, in the opinion of the investigator, would confound or interfere with study participation or the assessment of the safety, tolerability, or pharmacokinetics of the study drug.
[0523] Treatment naive subjects who met the exclusion criteria of Example 6 were not eligible for inclusion in this study.
[0524] 5. Prohibitions and Restrictions
[0525] Use the same prohibitions and restrictions on research participation used in Research Example 6.
[0526] B. Test product, dose and route of administration; regimen; duration of treatment
[0527] 1. For OL treatment period
[0528] All subjects received aproxetine and continued to take study medication once daily starting on Day 2 until the end of the treatment period. The test product, aproxetine, was supplied as 10 mg tablets in 35-count high-density polyethylene bottles.
[0529] 2. For the randomized treatment period
[0530] Subjects randomized to aproxetine received aproxetine tablets and continued to take study medication once daily starting in the morning after randomization (Day 2) until the end of the treatment period. The test product, aproxetine, was supplied as 10 mg tablets in 35- or 5-count high-density polyethylene bottles and labeled in a blinded manner (i.e., the bottle labels for the test product did not differ from those for the reference product except for the coded unique bottle number).
[0531] 3. For two treatment periods
[0532] Aproxetine was administered orally at approximately the same time each morning, regardless of food intake, with approximately 8 ounces of water.
[0533] C. Reference product, dose and route of administration; regimen; duration of treatment
[0534] 1. For OL treatment period
[0535] No subjects received the reference product during the OL treatment period.
[0536] 2. For the randomized treatment period
[0537] Subjects randomized to PBO received PBO tablets that were identical to aproxetine tablets in excipient content (except aproxetine), appearance, number of tablets, and in packaging (e.g., the bottle label of the reference product did not differ from the test product except for the coded unique bottle number).
[0538] PBO tablets are administered orally at approximately the same time each morning, regardless of food intake, with approximately 8 ounces of water.
[0539] D. Study Execution
[0540] 1. Open-label period (weeks 1 to 16)
[0541] Subjects enrolled in the OL phase of the study were scheduled to be visited on Day 15, Day 29, and every 4 weeks thereafter for assessments outlined in the Study Procedure Schedule. At V3 (Week 4), after the initial 4 weeks of OL treatment, subjects must demonstrate a decrease in OHSA#1 of at least 2 points from baseline values, as determined in Example 6 for subjects entering from Example 6 and from V1 for treatment-naive subjects, in order to continue in the study. Those subjects who did not meet this continuation criterion discontinued the study and had an end-of-study visit. The end-of-study visit was completed within 2 weeks from the date of the last dose.
[0542] All subjects who completed the initial 4-week OL treatment period and met continuation criteria continued to receive open-label aproxetine for an additional 12 weeks (16 weeks total).
[0543] 2. Double-blind period (weeks 17 to 22)
[0544] After completing a total of 16 weeks of OL aproxetine treatment (V6), subjects were evaluated for randomization in a 1:1 manner. Eligible subjects received 6 weeks of double-blind treatment with either aproxetine or PBO once daily. Only subjects with an OHSA #1 score ≤ 7 were eligible for randomization to the double-blind treatment period.
[0545] 3. Treatment period (weeks 1 to 22)
[0546] Dose reductions were not allowed during this treatment period. Subjects who were unable to tolerate 10 mg of aproxetine were discontinued from the study. At any time during the study, if a subject met at least one of the following stopping rules, the subject was discontinued from the study and had an end-of-study visit:
[0547] (a) The PI determines that further administration of the investigational product may pose a safety concern to the individual;
[0548] (b) SBP ≥ 180 mmHg or diastolic BP (DBP) ≥ 110 mmHg continuously (for at least 4 hours) after standing for 3 minutes or sitting for 5 minutes, or SBP ≥ 180 mmHg or DBP ≥ 110 mmHg continuously (for at least 4 hours) when measured in the supine position (head / trunk elevated approximately 30° from horizontal);
[0549] (c) an AE determined by the PI to be intolerable; or
[0550] (d) Individual pregnancy.
[0551] Safety assessments included physical examination, neurological examination, vital signs (temperature, HR, respiratory rate, and blood pressure), weight, 12-lead electrocardiogram, laboratory tests (hematology, chemistry, and urinalysis), Columbia-Suicide Severity Rating Scale (C-SSRS), and AE monitoring. Safety was reviewed regularly by an independent data monitoring committee (IDMC).
[0552] Subjects were asked to avoid any major dietary changes throughout the study period. Subjects were reminded to maintain adequate fluid intake during scheduled visits.
[0553] Subjects who completed the 6-week double-blind treatment period were eligible to continue in the OL long-term safety study (Study 0171). Subjects who did not complete the 6-week double-blind treatment period or chose not to continue in Study 0171 completed an early termination visit (V9) or a follow-up visit (V10), respectively. The follow-up visit was completed 2 weeks from the date of the last dose.
[0554] 4. Continue Standard
[0555] At V3 (Week 4), after the initial 4 weeks of OL treatment, subjects must demonstrate a decrease in OHSA #1 of at least 2 points from baseline values as determined in Example 6 for subjects entering from Example 6 and from V1 for treatment-naive subjects in order to continue in this study.
[0556] 5. Randomization criteria for the double-blind period
[0557] The following randomization criteria were used during the double-blind period.
[0558] (a) The individual's OHSA#1 score is ≤7.
[0559] (b) Subjects returned unused OL study medication (10 mg aproxetine tablets) to the study center.
[0560] (c) During the OL treatment period, the subject's compliance with study medication was at least 80%.
[0561] (d) Exclude subjects whose disease or symptoms worsen excessively during the OL period and who the investigators believe will not benefit from continued participation in the study.
[0562] E. Research Assessment
[0563] Efficacy assessments for this study include: OHQ and PGI-S; and symptom improvement in individuals measured by wearable devices. Exploratory assessments include: Upright Stand Test; NMSS; EQ-5D-5L; HADS; and BSFC-s. For individuals with PD, exploratory assessments include: Unified Parkinson's Disease Rating Scale (UPDRS); and Parkinson's Disease Questionnaire-8 (PDQ-8). For individuals with MSA, exploratory assessments include: Unified Multiple System Atrophy Rating Scale (UMSARS); and Composite Autonomic Symptom Score-31 (COMPASS-31).
[0564] Safety and tolerability assessments for this study included: physical examination, including weight; neurologic examination; vital signs, including gait BP; resting ECG; clinical laboratory evaluations, including serum chemistry, hematology, and urinalysis; concomitant medications; AEs; and C-SSRS.
[0565] A sparse PK sampling strategy was adopted in this study, in which samples were collected at selected study visits defined in the study procedure schedule. The time of study medication intake was accurately recorded on the day before and on the day of each study visit for PK sample collection.
[0566] At selected study visits as defined in the study procedure schedule, blood samples were collected 30 minutes after the subject was seated for analysis of pharmacodynamic markers ([dihydroxyphenylglycol] DHPG and NE). This was applied to all consenting subjects.
[0567] F. Statistical methods
[0568] 1. Sample size
[0569] The total planned sample size for randomization was 154, which was designed to provide 90% power to detect a 0.25 difference (0.25 aproxetine vs. 0.50 placebo) in the proportion of individuals meeting treatment failure criteria at week 6 of the double-blind randomized withdrawal period (V9, D155) using a two-sided test at the 0.05 significance level. The actual total sample size for randomization was 128.
[0570] 2. Study End Points
[0571] The primary study endpoint was the proportion of treatment failures during the double-blind randomized withdrawal period at week 6. Treatment failure was defined as individuals meeting the following criteria at week 6 after randomization (V9, D155): a 1.0-point change (worsening) in OHSA#1 score from baseline and a worsening of disease severity as assessed by a 1-point change in PGI-S.
[0572] The assessment performed at the Week 16 (V6, D113) visit in the pre-randomization OL phase was considered the baseline for the double-blind randomized withdrawal phase of the study. Subjects who withdrew for any reason before V9 (D155) or failed to provide an assessment at V9 (D155) were considered treatment failures.
[0573] Secondary endpoints include:
[0574] (a) Change from baseline in OHSA#1 at week 6 (V9, D155) after randomization;
[0575] (b) Change from baseline in OHSA composite score at week 6 (V9, D155) after randomization;
[0576] (c) Change from baseline in OHDAS composite score at week 6 (V9, D155) after randomization;
[0577] (d) Change in PGI-S from baseline at week 6 (V9, D155) after randomization;
[0578] (e) change from baseline in percentage of standing time measured by a wearable device at week 6 after randomization (V9, D155); and
[0579] (f) Change from baseline in mean step count measured by a wearable device at week 6 after randomization (V9, D155).
[0580] Exploratory endpoints include:
[0581] (a) Standing SBP during upright standing test at week 6 after randomization (V9, D155);
[0582] (b) Change from baseline in OHQ global composite score at week 6 (V9, D155) after randomization;
[0583] (c) change from baseline in EQ-5D-5L at week 6 after randomization (V9, D155);
[0584] (d) NMSS at week 6 after randomization (V9, D155);
[0585] (e) HADS at week 6 after randomization (V9, D155); and
[0586] (f) BSFC-s at week 6 after randomization (V9, D155).
[0587] For individuals with PD, exploratory endpoints include:
[0588] (a) Change from baseline in UPDRS at week 6 (V9, D155) after randomization; and
[0589] (b) Change from baseline in PDQ-8 at week 6 after randomization (V9, D155).
[0590] For individuals with MSA, exploratory endpoints included:
[0591] (a) Change from baseline in UMSARS at week 6 (V9, D155) after randomization; and
[0592] (b) Change from baseline in COMPASS-31 at week 6 after randomization (V9, D155).
[0593] Safety and tolerability endpoints included:
[0594] (a) Physical examination;
[0595] (b) Neurological examination;
[0596] (c) vital signs, including gait BP;
[0597] (d) ECG in recumbency;
[0598] (e) Clinical laboratory evaluation, including biochemistry, hematology, and urinalysis;
[0599] (f) concomitant medication;
[0600] (g) adverse events (AEs); and
[0601] (h) Columbia-Suicide Severity Rating Scale (C-SSRS).
[0602] Exploratory safety and tolerability endpoints included:
[0603] (a) PK and pharmacodynamic parameters.
[0604] 3. End point analysis
[0605] All efficacy analyses during the double-blind randomized-withdrawal period were performed based on the full analysis set (FAS) of the assigned randomized treatment. The FAS during the double-blind randomized-withdrawal period was defined as all randomized individuals who received at least 1 dose of study medication after randomization.
[0606] The safety analysis set was the same for the double-blind randomized withdrawal period.
[0607] The FAS and safety analysis sets for the OL phase were identical and were defined as all enrolled individuals who received at least 1 dose of aproxetine.
[0608] In the double-blind randomized withdrawal period, all data were summarized by treatment group. In the OL period, all data were summarized by overall and enrolled groups (placebo Example 6 completer group, aproxetine Example 6 completer group, and naive group). Descriptive statistics were used to summarize continuous variables. Categorical variables were summarized using individual counts and individual percentages in the corresponding categories.
[0609] The primary study endpoint was the proportion of treatment failures during the double-blind randomized withdrawal period at week 6. Treatment failure was defined as individuals meeting the following criteria at week 6 after randomization (V9, D155): a 1.0-point change (worsening) in OHSA#1 score from baseline and a worsening of disease severity as assessed by a 1-point change in PGI-S.
[0610] The assessment performed at the Week 16 (V6, D113) visit in the pre-randomization OL phase was considered the baseline for the double-blind randomized withdrawal phase of the study. Subjects who withdrew for any reason before V9 (D155) or failed to provide an assessment at V9 (D155) were counted as treatment failures.
[0611] A logistic regression model was fitted to estimate the effect of treatment on the primary endpoint. The model included treatment and baseline disease type (MSA, PAF, PD) terms, and also included baseline OHSA#1 score and baseline PGI-S terms as continuous covariates. Point estimates and 95% CIs for odds ratios are presented. The "least squares" treatment failure proportion (point estimate and standard error) for each treatment and disease type is also presented. In addition, the proportion of individuals with at least 1 point worsening of OHSA#1 and the proportion of individuals with at least 1 point worsening of PGI-S are also summarized.
[0612] The primary analysis was repeated on the per-protocol analysis set defined in the statistical analysis plan (SAP).
[0613] To assess the consistency of the aproxetine: placebo odds ratio for treatment failure across subgroups, the analysis of the primary endpoint was repeated for each subgroup specified in the SAP: MSA, PD, and PAF individuals; males and females; and individuals with baseline NE <200 pg / mL and ≥200 pg / mL. A forest plot is provided, which shows the aproxetine: placebo odds ratio point estimate and 95% CI for each subgroup.
[0614] Secondary endpoints were analyzed by fitting a repeated measures mixed model with the following terms: treatment, disease type (MSA, PD, PAF), visit, and treatment-visit interaction and endpoint baseline value as a continuous covariate. Intra-individual correlations were modeled using an unstructured variance-covariance matrix. The denominator degrees of freedom were estimated using the Kenward and Roger method. Missing endpoint values were assumed to be missing at random (MAR). The least squares means and 95% confidence intervals for the differences between aproxetine and placebo were calculated and presented.
[0615] Exploratory endpoints including assessment of change from baseline in standing SBP at multiple time points, such as during the upright stand test, were similarly analyzed.
[0616] Exploratory endpoints, including assessments such as change from baseline in PDQ-8, UPDRS, UMSARS, and COMPASS-31, but limited to week 6 after randomization (V9, D155), were analyzed by fitting an analysis of covariance model with the following terms: treatment, baseline disease type (MSA, PD, PAF), and endpoint baseline score as a continuous covariate.
[0617] A multiple testing plan was used to control the family-wise error type 1 error rate for the primary and secondary endpoints to 0.05. If the primary endpoint, a point estimate of the aproxetine:placebo ratio for treatment failure at week 6 (V9, D155) after randomization was <1 and p-value <0.05, the secondary efficacy endpoints were tested in the order shown below until the null hypothesis was first failed to be rejected:
[0618] 1. Change from baseline in OHSA#1 at week 6 (V9, D155) after randomization;
[0619] 2. Change from baseline in OHSA composite score at week 6 (V9, D155) after randomization;
[0620] 3. Change from baseline in OHDAS composite score at week 6 (V9, D155) after randomization;
[0621] 4. Change in PGI-S from baseline at week 6 (V9, D155) after randomization;
[0622] 5. Change from baseline in percentage of time spent standing (including walking) measured by a wearable device at week 6 after randomization (V9, D155);
[0623] 6. Change from baseline in mean step count measured by wearable device at week 6 after randomization (V9, D155).
[0624] For all other analyses, multiplicity was not adjusted.
[0625] Safety data were presented by topic and summarized descriptively. Summaries and tabulations of the OL period and the double-blind randomized withdrawal period were presented separately. Summary tables of vital signs, body weight, ECG, safety laboratory tests, C-SSRS, AEs, and concomitant medications were provided.
[0626] G. Study Results
[0627] In individuals with multiple system atrophy and symptomatic neurogenic orthostatic hypotension, it has been found that treatment with aproxetine for 22 weeks unexpectedly results in a measurable reduction in both: (i) the individual's symptoms of dizziness, lightheadedness, feeling faint, or feeling like they might pass out, as determined using the individual's OHSA Item 1 score; and (ii) the individual's global impression of symptom severity, as determined using the individual's OHSA Composite score. For example, Figure 1A showed that at the end of the 6-week double-blind randomized withdrawal period, MSA subjects who were administered placebo had worse OHSA Item 1 scores (+1.8) compared to subjects who were administered aproxetine (+0.3; p=0.0861); and Figure 1B It was shown that during the 6-week double-blind randomized withdrawal period, MSA subjects administered placebo had significantly worse OHSA composite scores (+1.54) compared to subjects administered aproxetine (-0.03; p=0.0056).
[0628] In individuals with multiple system atrophy and symptomatic neurogenic orthostatic hypotension, it has now also been found that treatment with aproxetine for 22 weeks unexpectedly resulted in a measurable decrease in the individual's Orthostatic Hypotension Daily Activities Scale (OHDAS) composite score and a measurable increase in the individual's systolic blood pressure after standing for 3 minutes. Figure 2A It was shown that in the 6-week double-blind randomized period of Example 7, MSA subjects administered placebo had significantly worse OHDAS composite scores (+0.97) compared to subjects administered aproxetine (+0.16; p=0.196). Figure 2B It was shown that during the 6-week double-blind randomized period, MSA subjects administered placebo had significantly worse systolic blood pressure after standing for 3 minutes (-12.4 mmHg) compared to subjects administered aproxetine (+6.1).
[0629] Figure 3 Results showed that at the end of the 6-week double-blind randomized period, OHSA and OHDAS composite scores and individual subscores for symptoms and daily activities in individuals with MSA were better with aproxetine, with the exception of the OHDAS prolonged walking test, which was better with placebo.
[0630] The OHSA Item 1 score is the OHQ item score, and the OHSA and OHDAS combined score is the OHQ subscale score (see Appendix 1 and, eg, Kaufman et al., Clinical Autonomous Research (2012), 22:79-90).
[0631] Additionally, in individuals with multiple system atrophy, it has been found that the decline in quality of life can be reduced when individuals are treated with aproxetine. Figure 4 It was shown that the quality of life of MSA individuals who were administered placebo decreased, while the quality of life of individuals who were administered aproxetine decreased less or improved. The EQ-5D-5L visual analog scale was used to measure quality of life (see Appendix 2; and, for example, McCaffrey et al., Health and Quality of Life Outcomes (2016) 14: 133).
[0632] Furthermore, it has been found that when individuals with multiple system atrophy are treated daily with aproxetine, the individuals' supine norepinephrine levels remain elevated for at least about 8 weeks, as shown in Table 8:
[0633] Table 8
[0634]
[0635] *All subjects received aproxetine in the open-label portion.
[0636] NE (pg / mL) is expressed as mean ± SD (n).
[0637] Table 8 shows that the supine norepinephrine (NE) level of individuals with MSA continues to rise after 4 weeks of treatment with aproxetine. Before treatment with aproxetine, the supine norepinephrine (NE) level of individuals with MSA was less than about 350 pg / mL. After about 8 weeks of treatment, the supine norepinephrine level was higher than about 500 pg / mL. Supine norepinephrine levels were determined using standard procedures (see, for example, Goldstein et al., Annals of Neurology, 1989: 26 (4) 558-563; and Palma et al., Neurology, 2018: 91 (16) e1539-e1544).
[0638] The OHSA and OHDAS scores at week 22 (end of the 6-week double-blind randomization period) were analyzed for the MSA subject subgroups and the results showed that aproxetine had better results in essentially all MSA subject subgroups. For example, Figure 5Table 9 shows that the OHSA composite scores of MSA individual subgroups were all better with aproxetine at Week 22. The subgroups included: MSA-Parkinson's disease type (MSA-P), MSA-cerebellar ataxia (MSA-C), nOH onset less than 1.6 years before the start of the study (nOH onset <1.6 years), nOH onset 1.6 years or more before the start of the study (nOH onset >=1.6 years), MSA diagnosed less than 1.3 years before the start of the study (MSA diagnosis <1.3 years), MSA diagnosed 1.3 years or more before the start of the study (MSA diagnosis >=1.3 years), Unified Multiple System Atrophy Rating Scale (UMSARS) Part 4 less than 4 (UMSARS Part IV <4), UMSARS Part IV 4 or higher (UMSARS Part IV >=4), male, female, less than 65 years old (<65 years), and 65 years old or older (>=65 years).
[0639] Table 9
[0640]
[0641] Surprisingly, aproxetine was able to treat or alleviate symptomatic nOH in patients with severe advanced or late-stage MSA, such as individuals with nOH onset 1.6 years or more before the start of the study, MSA diagnosis 1.3 years or more before the start of the study, MSA diagnosis less than 1.3 years before the start of the study, or UMSARS Part IV score of 4 or higher.
[0642] Table 10 shows that at Week 22, the OHDAS Item 1 (Activities Requiring Short-Term Standing) scores were mostly better with aproxetine in the subgroups of MSA individuals, including: MSA-Parkinson's disease (MSA-P), MSA-cerebellar ataxia (MSA-C), nOH onset less than 1.6 years before study entry (nOH onset <1.6 years), nOH onset 1.6 years or more before study entry (nOH onset >=1.6 years), MSA diagnosed less than 1.3 years before study entry (MSA diagnosis <1.3 years), MSA diagnosed 1.3 years or more before study entry (MSA diagnosis >=1.3 years), Unified Multiple System Atrophy Rating Scale (UMSARS) Part 4 less than 4 (UMSARS Part IV <4), male, female, less than 65 years old (<65 years), and 65 years old or older (>=65 years).
[0643] Table 10
[0644]
[0645]
[0646] Likewise, it was surprising that aproxetine was able to treat or alleviate symptomatic nOH in patients with relatively severe advanced or late-stage MSA, such as individuals with nOH onset 1.6 years or more before the start of the study, MSA diagnosis 1.3 years or more before the start of the study, MSA diagnosis less than 1.3 years before the start of the study, or UMSARS Part IV score of 4 or higher.
[0647] Figure 6 The results showed that at week 22 (end of the 6-week double-blind randomization period), the OHQ composite scores of MSA individual subgroups were all better with aproxetine. The subgroups included: MSA-Parkinson's disease type (MSA-P), MSA-cerebellar ataxia (MSA-C), nOH onset less than 1.6 years before the start of the study (nOH onset <1.6 years), nOH onset 1.6 years or more before the start of the study (nOH onset >=1.6 years), MSA diagnosed less than 1.3 years before the start of the study (MSA diagnosis <1.3 years), MSA diagnosed 1.3 years or more before the start of the study (MSA diagnosis >=1.3 years), Unified Multiple System Atrophy Rating Scale (UMSARS) Part 4 less than 4 (UMSARS Part IV <4), male, female, less than 65 years old (<65 years), and 65 years old or older (>=65 years).
[0648] Subgroup analysis also showed that although MSA is a progressive condition, aproxetine has a surprising benefit for individuals with different baseline severity levels of nOH. Table 11 shows the change in OHSA composite score at Week 22 (end of the 6-week double-blind randomized period) for subgroups of MSA individuals, each of which had a different degree of nOH before the double-blind randomized period (RW baseline) or before treatment (pre-treatment baseline), as shown by the OHSA composite score or OHSA Item 1 score.
[0649] Table 11
[0650]
[0651]
[0652] The study also showed that at week 22 (end of the 6-week double-blind randomized period), individuals with MSA who were administered aproxetine showed a reduction in total anxiety scores, indicating that aproxetine is effective for anxiety associated with MSA and / or nOH. Table 12 shows the change in total anxiety scores relative to baseline for MSA individuals at week 22. Total anxiety scores were determined using standard procedures (see, e.g., Rich et al., Hospital Anxiety and Depression Scale Assessment in 100 Patients Before and After Low Vision Care: A Prospective Study in a Tertiary Eye Care Facility, Indian Journal of Ophthalmology, November 2017; 65(11): 1203-1208).
[0653] Table 12
[0654]
[0655] Aproxetine showed greater improvements in anxiety associated with MSA and / or nOH compared to MSA subjects at week 4 as shown in Table 5 (Example 6), indicating that extended treatment (i.e., 4 weeks or longer) surprisingly provides greater effects. Similarly, aproxetine did not reach the endpoint at week 4 in Example 6, while extended administration of aproxetine showed significant improvements in nOH symptoms, as shown in Tables 9 to 11 and Figure 5 and 6 Thus, it is shown that, surprisingly, aproxetine exhibits efficacy when administered for a long period of time (ie, 4 weeks or more) that may not be exhibited when administered for a short period of time (ie, less than 4 weeks).
[0656] Example 8
[0657] Phase 3 efficacy and durability of aproxetine for the treatment of symptomatic nOH in individuals with multiple system atrophy
[0658] This is a Phase 3, multicenter, randomized discontinuation and long-term extension study to evaluate the efficacy and durability of sustained benefit of aproxetine (administered as aproxetine hydrochloride) after 20 weeks of treatment in individuals with MSA and symptomatic nOH. Eligible subjects were individuals with MSA and symptomatic nOH who met all applicable study inclusion criteria and did not meet any applicable exclusion criteria.
[0659] The study consisted of 4 phases: (i) a screening phase of up to 14 days, (ii) a 12-week open-label (OL) aproxetine treatment phase, (iii) an 8-week double-blind randomized placebo-controlled treatment phase, and (iii) a 2-year long-term extension phase.
[0660] A. Study Group
[0661] This study enrolled adult individuals with MSA and confirmed symptomatic nOH who met all applicable inclusion criteria defined below and did not meet any applicable exclusion criteria.
[0662] 1. Inclusion criteria
[0663] Individuals who met the following applicable criteria were eligible for inclusion in the study.
[0664] (a) The individual is male or female and is at least 30 years old.
[0665] (b) Individuals were diagnosed with possible or probable MSA parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) according to Gilman criteria (2008).
[0666] (c) Subjects were diagnosed with possible or probable MSA parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) and confirmed by the Enrollment Steering Committee (ESC).
[0667] (d) Subjects must meet diagnostic criteria for nOH as demonstrated by a sustained decrease in BP of ≥20 mmHg (systolic) or ≥10 mmHg (diastolic) within 3 minutes of standing as part of the upright stand test or tilting upward ≥60° from the supine position as determined by a tilt table test.
[0668] (e) At Visit 1 (Screening), the individual must have a UMSARS Part IV score of ≤4.
[0669] (f) At Visit 2 (Day 1), the individual must have an OHSA Item 1 score of at least 4.
[0670] (g) Subjects must be willing not to take any prohibited medications during the study.
[0671] (h) If the individual is female, the individual must not be pregnant, nursing, or planning to become pregnant during the course of the study. Females of childbearing potential must have a documented negative pregnancy test result at screening. Females are considered to be of childbearing potential unless they are postmenopausal (amenorrhea for at least 2 years) or have documented surgical sterilization (bilateral tubal ligation or total hysterectomy). Female individuals may be admitted to the study based on a negative urine pregnancy test result. If the urine beta human chorionic gonadotropin (bHCG) test is positive, a serum bHCG test must be performed. A negative pregnancy test must be confirmed for an individual to be eligible to participate in this study.
[0672] (i) Females of childbearing potential or males of childbearing potential must agree to use highly effective contraceptive measures (failure rate < 1% when used consistently and correctly) or agree to refrain from sexual intercourse (see Section 4.3) during the study and for 30 days after the last dose of study drug.
[0673] (j) The individual is willing and able to provide signed and dated written informed consent prior to the commencement of any research-related procedures.
[0674] (k) The individual is able to communicate well with the investigators and clinic staff, understands the expectations of the study, and is able to comply with the study procedures, requirements, and limitations.
[0675] 4. Exclusion criteria
[0676] Individuals meeting any of the following criteria were not eligible for inclusion in the study.
[0677] (a) Individuals have systemic diseases known to produce autonomic neuropathy, including but not limited to amyloidosis and autoimmune neuropathy. Individuals with diabetes mellitus (DM) are evaluated on a case-by-case basis by a medical monitor and are considered ineligible unless all of the following criteria are met:
[0678] 1. Type 2 DM can be well controlled with oral medication and diet alone
[0679] 2. HbA1C ≤ 7.5% during the screening period or up to 12 weeks prior to screening
[0680] 3. No clinically apparent peripheral neuropathy (e.g., normal sensory examination of the limbs)
[0681] 4. No known retinal disease (e.g., annual eye examinations are sufficient)
[0682] 5. No renal disease (eg, no albuminuria and GFR>60).
[0683] (b) The individual is known to be intolerant to other NRIs or SNRIs.
[0684] (c) The subject is currently using concomitant antihypertensive agents for the treatment of essential hypertension. (d) The subject has used a strong CYP1A2 inhibitor or inducer within 7 days or 5 half-lives (whichever is longer) before Visit 2 (Day 1), or concomitant use is required before the safety follow-up visit.
[0685] (e) The individual has changed the dose, frequency, or type of medication prescribed for orthostatic hypotension within the 7 days prior to Visit 2 (Day 1). Midodrine and droxidopa (if applicable) must be tapered and discontinued at least 7 days prior to Visit 2 (Day 1). (f) The individual has a known or suspected history of alcohol or drug abuse (Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Rev., Alcohol or Drug Abuse) within the past 12 months. (e) The individual has clinically unstable coronary artery disease or has had a major cardiovascular event (e.g., myocardial infarction) within the past 6 months.
[0686] (f) Subjects have a history of severe uncontrolled arrhythmias, complete heart block, or significant QTc prolongation (≥450 msec in males and ≥470 msec in females).
[0687] (g) The individual has had a new neurological event (i.e., seizure, confusion, altered level of consciousness, etc.) within the past 6 months.
[0688] (h) Subjects had used any monoamine oxidase inhibitors (MAOIs) within 14 days prior to Visit 2 (Day 1).
[0689] (i) The individual has a history of untreated angle-closure glaucoma or a history of treated angle-closure glaucoma that the ophthalmologist believes may place the individual at increased risk.
[0690] (j) Individuals had a Montreal Cognitive Assessment (MoCA) <21.
[0691] (k) The individual is unable or unwilling to complete all procedures specified in the protocol, including questionnaires.
[0692] (l) Subjects are known to have congestive heart failure (New York Heart Association [NYHA] class 3 or 4).
[0693] (m) The individual has had any malignant disease other than cervical carcinoma in situ or basal cell carcinoma in the past 2 years before screening.
[0694] (n) Subjects are known to have gastrointestinal (GI) conditions that, at the discretion of the investigator, may affect absorption of the study agent (eg, ulcerative colitis, gastric bypass surgery).
[0695] (o) The subject suffers from a mental, neurological, or behavioral disorder that may interfere with the subject's cognitive ability to give informed consent, understand and comply with research procedures, or interfere with the conduct of the research.
[0696] (p) The individual is currently receiving any investigational drug or has received an investigational drug within 30 days of administration. Investigational drugs are defined as drugs that have not been approved by a regulatory agency (e.g., the Food and Drug Administration [FDA]).
[0697] (q) The subject has clinically significant abnormal laboratory findings (e.g., alanine aminotransferase [ALT] or aspartate aminotransferase [AST] ≥ 3.0 × upper limit of normal [ULN]; blood bilirubin [total] ≥ 3.0 × ULN; estimated glomerular filtration rate (eGFR) < 30 mL / min / 1.73 m2; or any abnormal laboratory value that could interfere with the safety of the subject).
[0698] (r) The individual has demonstrated lifetime suicidal ideation and / or suicidal behavior as outlined by the C-SSRS (baseline / screening version). The assessor should assess the individual's risk for suicide and the appropriateness of the individual for inclusion in the study.
[0699] (s) The subject has or has undergone a concurrent illness or condition (e.g., COVID-19) or recent surgery that the investigator believes will confound or interfere with study participation or the assessment of the safety, tolerability, or absorption of the study drug.
[0700] (t) The individual has a known hypersensitivity to aproxetine (aproxetine hydrochloride) or any of the excipients in the formulation.
[0701] (u) Major surgery (i.e., surgery with a higher risk of infection and a longer recovery period, such as joint replacement, gastric bypass, open heart surgery, organ transplantation, etc.) within 4 weeks before enrollment.
[0702] B. Test product, dose and route of administration; regimen; duration of treatment
[0703] 1. For OL treatment period
[0704] All subjects received aproxetine and continued to take study medication once daily starting on Day 2 until the end of the OL period. The test product was aproxetine supplied as 10 mg tablets in 30-count high-density polyethylene bottles.
[0705] 2. For RW period
[0706] Subjects randomized to aproxetine received aproxetine tablets and continued to take study medication once daily starting in the morning after Visit 5 (Day 2 of the RW period, Day 86) until the end of the RW period. The test product was aproxetine, which was supplied as 10 mg tablets in 30-count high-density polyethylene bottles and labeled in a blinded manner (i.e., the bottle labels for the test product did not differ from those for the reference product except for the coded unique bottle number).
[0707] 3. For LTE treatment period
[0708] Subjects received aproxetine and continued to take study medication once daily starting on Day 142 until the end of the LTE period. The test product was aproxetine supplied as 10 mg tablets in 30-count high-density polyethylene bottles.
[0709] 4. For all treatment periods
[0710] Aproxetine was administered orally at approximately the same time each morning, regardless of food intake, with approximately 8 ounces (240 mL) of water.
[0711] C. Reference product, dose and route of administration; regimen; duration of treatment
[0712] 1. For OL treatment period
[0713] No subjects received the reference product during the OL treatment period.
[0714] 2. For RW period
[0715] Individuals randomized to PBO received a placebo tablet once daily starting on the morning after Visit 5 (Day 2 of the RW period, Day 86) until the end of the RW period. The PBO tablets were identical to the aproxetine tablets in excipient content (except for the absence of aproxetine), appearance, number of tablets, and packaging (i.e., the bottle label of the reference product did not differ from that of the test product except for the coded unique bottle number).
[0716] 3. For LTE
[0717] No subjects received the reference product during the LTE treatment period.
[0718] 4. For all treatment periods
[0719] PBO tablets are administered orally at approximately the same time each morning, regardless of food intake, with approximately 8 ounces of water.
[0720] D. Study Execution
[0721] 1. filter
[0722] Individuals enter a screening period of up to 14 days to confirm eligibility. At the first visit (screening), individuals provide a complete medical history of their disease and treatment. The principal investigator (PI) or assistant researcher describes and records the individual's disease. Individuals receive an assessment of their physical condition, including safety and laboratory assessments and relevant aspects of their disease state. Eligible individuals will receive training on how to accurately score the items of the OHQ. After the screening period (up to 14 days), individuals continue to visit 2 (Day 1) to further confirm other eligibility criteria before continuing. This includes completing the OHQ, which requires a minimum score of 4 points for the first item of the OHSA. Individuals who meet all inclusion criteria, do not meet any exclusion criteria, and whose disease characteristics are confirmed by the Independent Enrollment Steering Committee (ESC) receive aproxetine during the OL period.
[0723] 2. Open-label period (weeks 1 to 12)
[0724] Beginning on day 2 (the morning after visit 2), subjects received a single dose of OL 10 mg aproxetine once daily and continued the OL period for 12 weeks thereafter.
[0725] Subjects enrolled in the OL phase of the study were scheduled to have visits on Day 29 (Visit 3, Week 4), Day 57 (Visit 4, Week 8), and Day 85 (Visit 5, Week 12) as outlined in the Study Procedure Schedule (Table 1). At Visit 4, after 8 weeks of OL treatment, subjects had to demonstrate a decrease of at least 2 points on OHSA Item 1 compared to the baseline value (i.e., the value measured at Visit 2) in order to continue in the study.
[0726] All subjects who met continuation criteria at Visit 4 (Week 8) continued to receive OL aproxetine tablets for an additional 4 weeks (12 weeks total).
[0727] Those subjects who do not meet this continuation criterion at Visit 4 must discontinue the study and have an early termination visit within 3 days of the last dose. The safety follow-up visit (end of study) must be completed within 30 days (± 7 days) of the date of the last dose and can be conducted in the clinic or by telephone.
[0728] 3. Double-blind randomized withdrawal period (weeks 13 to 20)
[0729] After completing a total of 12 weeks of OL aproxetine treatment, subjects were evaluated at Visit 5 for randomization in a 1: 1 manner. Only subjects with an OHSA Item 1 score of ≤7 were eligible for randomization to the double-blind treatment period.
[0730] Eligible subjects received double-blind treatment with 10 mg aproxetine or placebo once daily for 8 weeks.
[0731] Once 25% (ie, 18 randomized individuals) is reached, randomization (Visit 5) will be capped at individuals with a UMSARS Part IV score of 4 at Screening (Visit 1).
[0732] Subjects who are not eligible for randomization must discontinue the study and have an early termination visit within 3 days of the last dose. The safety follow-up visit (end of study visit) must be completed within 30 days (± 7 days) of the date of the last dose and can be conducted in the clinic or by telephone.
[0733] 4. Treatment period (weeks 1 to 22)
[0734] Dose reductions were not allowed during the treatment period. Subjects who were unable to tolerate 10 mg aproxetine were discontinued from the study. At any time during the study, if a subject met at least one of the following stopping rules, they should be discontinued from the study and have an early termination visit and a safety follow-up visit (end of study visit):
[0735] (a) The PI determines that further administration of the investigational product may pose a safety concern to the individual
[0736] (b) SBP ≥ 180 mmHg or diastolic BP (DBP) ≥ 110 mmHg continuously (for at least 4 hours) after standing for 3 minutes or sitting for 5 minutes, or SBP ≥ 180 mmHg or DBP ≥ 110 mmHg continuously (for at least 4 hours) measured in the supine position (head / trunk elevated approximately 30° from horizontal position).
[0737] (c) AEs determined to be intolerable by the investigator
[0738] (d) Female individual pregnancy
[0739] Safety assessments included physical examination, neurologic examination, vital signs (temperature, HR, respiratory rate [RR], and BP), weight, 12-lead ECG, laboratory tests (hematology, chemistry, and urinalysis), Columbia-Suicide Severity Rating Scale (C-SSRS), and AE monitoring.
[0740] Subjects were asked to avoid any major dietary changes throughout the study period. Subjects were reminded to maintain adequate fluid intake during scheduled visits.
[0741] For those individuals who did not complete the 8-week double-blind RW phase, the individual completed an early termination visit within 3 days from the date of the last dose. For all individuals, a safety follow-up visit (end of study visit) must be completed within 30 days (± 7 days) from the date of the last dose and can be performed in an outpatient clinic or by telephone. Individuals who completed the 8-week double-blind RW phase are eligible to continue into the 2-year LTE phase.
[0742] 5. Long-term treatment extension
[0743] During the LTE, subjects received 10 mg of aproxetine once daily and attended study visits consistent with the standard of care for subjects outside of a clinical trial or at least annual clinic visits (Table 1).
[0744] All sites are open to outpatient or remote unscheduled visits at the discretion of the investigator outside of the routine visit schedule for individual safety or unexpected individual medical needs. Data collected during these visits may include any protocol-specified assessments captured in the clinical database.
[0745] The safety follow-up visit (end of study) must be completed within 30 days (± 7 days) from the date of the last dose and can be conducted in the clinic or by telephone.
[0746] E. Research Assessment
[0747] Efficacy assessments for this study included: OHQ, OST (upright standing test) (including a 3-minute stand test), and pharmacokinetic assessments.
[0748] Exploratory assessments included: Hospital Anxiety and Depression Scale (HADS), Patient Global Impression of Severity-Symptoms (PGIS-Symptoms), Patient Global Impression of Severity-Activities (PGIS-Activities), Patient Global Impression of Change-Symptoms (PGIC-Symptoms), and Patient Global Impression of Change-Activities (PGIC-Activities).
[0749] Safety and tolerability assessments for this study included: C-SSRS; AEs; medication and medical history, physical examination; neurologic examination; height and weight; vital signs, ECG; laboratory tests, hematology, chemistry, urinalysis, dosing diary assignment and / or collection; and unscheduled visits.
[0750] F. Statistical methods
[0751] 1. Sample size
[0752] A total sample size of 64 would provide greater than 90% overall power to detect a 1.5-point difference in the primary endpoint of change in OHSA composite score at Week 8 (Visit 9, Day 141) during the double-blind RW phase, with a standard deviation of 1.8 points and a two-sided alpha level of 0.05. Power calculations included a single interim analysis with a power of approximately 56% of individuals, where a Hwang-Shih-DeCani alpha-spending function with a gamma parameter (-3.5) was constructed to achieve group sequential bounds to control the type I error rate. A sample size of 72 was required at randomization (Visit 5) to account for a 10% dropout rate during the RW phase.
[0753] Assuming 70% of individuals are eligible for randomization at the end of the 12-week OL period, approximately 102 individuals will be included to ensure that an estimated 72 individuals will continue into the randomized treatment period.
[0754] 2. Study End Points
[0755] The primary study endpoint was the change in OHSA composite score at Week 8 (Visit 9, Day 141) during the double-blind RW phase. The assessment performed at Week 12 (Visit 5, Day 85) during the pre-randomization OL phase was considered the baseline for the double-blind RW phase of the study.
[0756] Secondary endpoints were:
[0757] (a) Change from baseline in OHDAS Item 1 (Activities requiring standing for short periods of time) at Week 8 after randomization (Visit 9, Day 141)
[0758] (b) Change from baseline in OHDAS item 3 (activities requiring short walking) at week 8 after randomization (visit 9, day 141)
[0759] Exploratory endpoints include:
[0760] (c) Change from baseline in 3-minute standing SBP during OST at week 8 after randomization (visit 9, day 141)
[0761] (d) Change from baseline in OHQ composite score at week 8 after randomization (visit 9, day 141)
[0762] (e) Change from baseline in the composite score of short daily activities (OHDAS-1 and OHDAS-3) at week 8 after randomization (visit 9, day 141); the composite score of short daily activities was defined as the mean of the scores of OHDAS-1 and OHDAS-3 in the OHQ questionnaire.
[0763] (f) Change from baseline in the HADS anxiety domain at week 8 after randomization (visit 9, day 141)
[0764] (g) Change from baseline in the HADS depression domain at week 8 after randomization (visit 9, day 141)
[0765] (h) PGIS-symptoms and PGIS-activity at baseline and at week 8 after randomization (visit 9, day 141)
[0766] (i) Change from baseline in PGIS-symptoms and PGIS-activity at week 8 after randomization (visit 9, day 141)
[0767] (j) PGIC-symptoms and PGIC-activity at 8 weeks after randomization (Visit 9, Day 141)
[0768] 3. End point analysis
[0769] The primary outcome measure addressed the following clinical question of interest: mean difference in change in OHSA composite score at Week 8 in individuals with MSA and symptomatic nOH treated with aproxetine versus placebo, regardless of discontinuation of the study intervention for any reason and regardless of initiation of rescue medication, during the double-blind RW phase.
[0770] The main measures measured follow the treatment policy strategy and are described by the following attributes:
[0771] (a) Population: individuals with MSA and symptomatic nOH (ie, FAS in the double-blind RW phase).
[0772] (b) Endpoint: Change in OHSA composite score at week 8 during the double-blind RW phase.
[0773] (c) Treatment condition: study intervention, regardless of discontinuation for any reason, regardless of the use of rescue medication (treatment policy strategy).
[0774] (d) Group-level summary: the difference in mean change between treatment conditions.
[0775] The main treatment differences based on FAS were estimated using a repeated measures mixed model (MMRM) analysis. The model included the following fixed effect category terms: treatment, UMSARS Part IV (<4,4) and visits at the 1st visit, baseline scores as continuous covariates (5th visit, 85th day) and random individual effects and unstructured covariance structures. The interaction terms of visit*treatment and visit*baseline were also included. If the model does not converge, composite symmetry or other covariance structures are used as alternative covariance structures. The least squares means and 95% confidence intervals of the differences between aproxetine and placebo were calculated and presented. It was assumed that missing data were missing at random (MAR).
[0776] Sensitivity analyses of the primary analysis were performed with multiple imputation using the missing-not-at-random method for missing data. The strategy for supplementing the estimated data was specified in the statistical analysis plan (SAP).
[0777] The primary analysis was repeated for a set of prespecified subgroups and presented in graphical format. Details are specified in SAP.
[0778] Individual components of the OHSA composite score were presented as supportive analyses and were analyzed using a repeated measures mixed model (MMRM) similar to that outlined for the primary analysis.
[0779] There are four key secondary estimators of interest that follow the treatment policy strategy and have the same treatment condition, residual concomitant events, and population-level summary properties as the primary endpoint. The population and estimator properties are as follows:
[0780] Key secondary estimated 1
[0781] (a) Population: Individuals with MSA and symptomatic nOH and UMSARS Part IV < 4 at Visit 1
[0782] (b) Endpoint: Change from baseline in the effect of symptoms on activities requiring standing for a short period of time (OHDAS Item 1) at 8 weeks after randomization (Visit 9, Day 141).
[0783] Key secondary estimated 2
[0784] (a) Population: Individuals with symptomatic nOH caused by MSA
[0785] (b) Endpoint: Change from baseline in the effect of symptoms on activities requiring standing for a short period of time (OHDAS Item 1) at 8 weeks after randomization (Visit 9, Day 141).
[0786] Key secondary estimated 3
[0787] (a) Population: Individuals with symptomatic nOH caused by MSA and UMSARS Part IV < 4 at Visit 1
[0788] (b) Endpoint: Change from baseline in the effect of symptoms on activities requiring short walking (OHDAS item 3) at week 8 after randomization (visit 9, day 141)
[0789] Key secondary estimated 4
[0790] (a) Population: Individuals with symptomatic nOH caused by MSA
[0791] (b) Endpoint: Change from baseline in the effect of symptoms on activities requiring short walking (OHDAS item 3) at week 8 after randomization (visit 9, day 141)
[0792] Secondary efficacy endpoints were analyzed using MMRM to compare treatment differences. The model in the UMSARS Part IV<4 subgroup analysis included the following fixed effect category terms: treatment, visit, and baseline scores, random individual effects, and unstructured covariance structures of the corresponding measurements as continuous covariates. Interaction terms of visit*treatment and visit*baseline were included. If the model does not converge, composite symmetry or other covariance structures are used as alternative covariance structures. The least squares mean and 95% confidence interval of the difference between aproxetine and placebo are calculated and presented. The analysis model in the complete population also includes the following fixed effect category terms: UMSARS Part IV (<4,4) at the 1st visit.
[0793] The following exploratory endpoints were analyzed similarly to the primary analysis, including assessment of changes from baseline in, for example, the OHQ composite score at multiple time points.
[0794] For exploratory endpoints including assessments such as change in HADS range from baseline but limited to Week 8 after randomization (Visit 9, Day 141), analysis of covariance (ANCOVA) was used to compare treatment differences based on FAS. The model included fixed treatment effects and baseline score of the corresponding scale as a continuous covariate.
[0795] SAP details the analyses of PGIS and PGIC to support the interpretation of the primary and secondary endpoints.
[0796] In addition, descriptive analyses were performed on efficacy data collected for all individuals during the OL period.
[0797] ***
[0798] Although the subject matter of the present disclosure has been described with reference to certain aspects or embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the present disclosure. In addition, to the extent permitted by applicable patent provisions and regulations, all publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety to the same extent as if each document were individually incorporated by reference herein.
Claims
1. A method for treating symptomatic neurogenic orthostatic hypotension (nOH) in a subject with multiple system atrophy (MSA), the method comprising administering to the subject daily for at least about 8 weeks a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of ampreloxetine or a pharmaceutically acceptable salt thereof, wherein the administration results in a decrease in at least one of the Orthostatic Hypotension Symptom Assessment (OHSA) composite score, the Orthostatic Hypotension Daily Activities Scale (OHDAS) Item 1 score (short duration standing), and the OHDAS Item 3 score (short duration walking).
2. The method of claim 1, wherein the pharmaceutical composition is administered to the subject orally.
3. The method of claim 1 or 2, wherein the pharmaceutical composition is administered to the subject once daily.
4. The method of any one of claims 1 to 3, wherein the individual treated has symptoms of neurogenic orthostatic hypotension in the absence of treatment with the pharmaceutical composition as determined using the Orthostatic Hypotension Assessment Scale (OHSA).
5. The method of any one of claims 1 to 4, wherein the subject has MSA P subtype (MSA-P).
6. The method of any one of claims 1 to 4, wherein the individual has MSA subtype C (MSA-C).
7. The method of any one of claims 1 to 6, wherein prior to treatment, the subject's BP has sustained a decrease of ≥20 mmHg (systolic) or ≥10 mmHg (diastolic) within 3 minutes of standing as part of an upright stand test or tilting upward ≥60° from a supine position as determined by a tilt table test.
8. The method of any one of claims 1 to 7, wherein prior to treatment, the subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of 4 or less.
9. The method of any one of claims 1 to 7, wherein prior to treatment, the subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of 4.
10. The method of claims 1 to 9, wherein prior to said administering, said subject has an OHSA Item 1 score of at least 4.
11. The method of claims 1-10, wherein the pharmaceutical composition is administered for at least about 12 weeks.
12. The method of any one of claims 1 to 11, wherein aproxetine is administered as a hydrochloride salt.
13. The method of any one of claims 1 to 12, wherein the pharmaceutically acceptable carrier comprises one or more of microcrystalline cellulose, lactose, and magnesium stearate.
14. A method for treating symptomatic neurogenic orthostatic hypotension (nOH) in a subject with multiple system atrophy (MSA), the method comprising administering to the subject daily for at least about 22 weeks a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof, wherein: (a) the individual being treated experiences symptoms of neurogenic orthostatic hypotension in the absence of treatment with the pharmaceutical composition, as determined using the Orthostatic Hypotension Assessment Scale (OHSA); and (b) daily administration of the pharmaceutical composition to the subject for at least about 22 weeks causes a measurable decrease in at least one of: (i) the subject's OHSA composite score, (ii) Orthostatic Hypotension Questionnaire (OHQ) composite score, (iii) Orthostatic Hypotension Daily Activities Scale (OHDAS) composite score, or (iv) OHDAS Item 1 (Short-term Standing).
15. The method of claim 14, wherein the pharmaceutical composition is administered to the subject orally.
16. The method of claim 14 or 15, wherein the pharmaceutical composition is administered to the subject once daily.
17. The method of any one of claims 14 to 16, wherein prior to treatment with the pharmaceutical composition, the subject has a supine plasma norepinephrine level of less than about 350 pg / mL.
18. The method of any one of claims 14 to 16, wherein the subject has a supine plasma norepinephrine level above about 500 pg / mL after about 8 weeks of treatment with the pharmaceutical composition.
19. The method of any one of claims 14 to 18, wherein the subject has MSA P subtype (MSA-P).
20. The method of any one of claims 14-19, wherein the subject has been diagnosed with MSA at least 1.3 years prior to said administering.
21. The method of any one of claims 14-20, wherein the subject developed nOH 1.6 years or more prior to the administering.
22. The method of any one of claims 14-21, wherein prior to said administering, said subject has an OSHA composite rating of 5 or greater.
23. The method of any one of claims 14-22, wherein prior to said administering, said subject has an OSHA Part 1 rating of 7 or greater.
24. The method of any one of claims 14-23, wherein prior to said administering, said subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of ≤4.
25. The method of any one of claims 14-23, wherein prior to said administering, said subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of 4.
26. The method of any one of claims 14-25, wherein aproxetine is administered as a hydrochloride salt.
27. The method of any one of claims 14-26, wherein the pharmaceutical composition is administered for at least about 12 months.
28. The method of any one of claims 14 to 27, wherein the pharmaceutically acceptable carrier comprises one or more of microcrystalline cellulose, lactose, and magnesium stearate.
29. A method of identifying an individual with multiple system atrophy (MSA) who is responsive to aproxetine, comprising: The subject is administered a pharmaceutical composition comprising a pharmaceutically acceptable carrier and about 10 mg (free base equivalent) of aproxetine or a pharmaceutically acceptable salt thereof for at least 8 weeks.
30. The method of claim 29, wherein the pharmaceutical composition is administered for at least 12 weeks.
31. The method of claim 29 or 30, further comprising determining whether the subject's Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 score decreases by at least 2 points following the administration.
32. The method of any one of claims 29-31, wherein the pharmaceutical composition is administered to the subject orally.
33. The method of any one of claims 29-32, wherein the pharmaceutical composition is administered to the subject once daily.
34. The method of any one of claims 29 to 33, wherein the MSA is MSA P subtype (MSA-P).
35. The method of any one of claims 29-33, wherein the MSA is MSA subtype P (MSA-C).
36. A method of treating symptomatic neurogenic orthostatic hypotension (nOH) in a subject with multiple system atrophy (MSA), comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and aproxetine or a pharmaceutically acceptable salt thereof, wherein the subject: (a) an Orthostatic Hypotension Assessment Scale (OSHA) composite score of 5 or greater prior to said administration; and / or (b) An OSHA Section 1 rating of 7 or higher prior to said administration.
37. A use of a pharmaceutical composition comprising aproxetine or a pharmaceutically acceptable salt thereof for treating symptomatic neurogenic orthostatic hypotension (nOH) in an individual with multiple system atrophy (MSA), wherein the pharmaceutical composition comprises about 10 mg (free base equivalent) of aproxetine, wherein the pharmaceutical composition is administered daily to the individual for at least about 8 weeks, and wherein the administration results in a decrease in at least one of the following: the Orthostatic Hypotension Symptom Assessment (OHSA) composite score, the Orthostatic Hypotension Daily Activities Scale (OHDAS) Item 1 score (short duration of standing), and the OHDAS Item 3 score (short duration of walking).
38. The use according to claim 37, wherein the pharmaceutical composition is administered to the subject orally.
39. The use according to claim 37 or 38, wherein the pharmaceutical composition is administered to the subject once a day.
40. The use according to any one of claims 37 to 39, wherein the individual treated suffers from symptoms of neurogenic orthostatic hypotension in the absence of treatment with the pharmaceutical composition as determined using the Orthostatic Hypotension Assessment Scale (OHSA).
41. The use of any one of claims 37 to 40, wherein the subject suffers from MSA P subtype (MSA-P).
42. The use according to any one of claims 37 to 40, wherein the subject suffers from MSA subtype C (MSA-C).
43. The use of any one of claims 37 to 42, wherein prior to the administration, the subject's BP has sustained a decrease of ≥20 mmHg (systolic blood pressure) or ≥10 mmHg (diastolic blood pressure) within 3 minutes of standing as part of an upright stand test or tilting upward ≥60° from a supine position as determined by a tilt table test.
44. The use of any one of claims 37 to 43, wherein prior to said administering, said subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of 4 or less.
45. The use of any one of claims 37 to 43, wherein prior to said administering, said subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of 4.
46. The use of any one of claims 37 to 45, wherein prior to said administering, said subject has an OHSA 1 score of at least 4.
47. The use of any one of claims 37 to 46, wherein the pharmaceutical composition is administered for at least about 12 weeks.
48. The use according to any one of claims 37 to 47, wherein aproxetine is administered in the form of the hydrochloride salt.
49. The use according to any one of claims 37 to 48, wherein the pharmaceutically acceptable carrier comprises one or more of microcrystalline cellulose, lactose and magnesium stearate.
50. A use of a pharmaceutical composition comprising aproxetine or a pharmaceutically acceptable salt thereof for treating symptomatic neurogenic orthostatic hypotension (nOH) in a subject suffering from multiple system atrophy (MSA), wherein the pharmaceutical composition comprises about 10 mg (free base equivalent) of aproxetine, wherein the pharmaceutical composition is administered daily to the subject for at least about 22 weeks, wherein: (a) the individual being treated experiences symptoms of neurogenic orthostatic hypotension in the absence of treatment with the pharmaceutical composition, as determined using the Orthostatic Hypotension Assessment Scale (OHSA); and (b) daily administration of the pharmaceutical composition to the subject for at least about 14 weeks causes a measurable decrease in at least one of: (i) the subject's OHSA composite score, (ii) the Orthostatic Hypotension Questionnaire (OHQ) composite score, (iii) the Orthostatic Hypotension Daily Activities Scale (OHDAS) composite score, or (iv) OHDAS Item 1 (Short-term Standing).
51. The use according to claim 50, wherein the pharmaceutical composition is administered to the subject orally.
52. The use according to claim 50 or 51, wherein the pharmaceutical composition is administered to the subject once a day.
53. The use of any one of claims 50 to 52, wherein prior to treatment with the pharmaceutical composition, the subject has a supine plasma norepinephrine level of less than about 350 pg / mL.
54. The use of any one of claims 50 to 53, wherein after about 8 weeks of treatment with the pharmaceutical composition, the subject has a supine plasma norepinephrine level above about 500 pg / mL.
55. The use of any one of claims 50 to 54, wherein the subject suffers from MSA P subtype (MSA-P).
56. The use of any one of claims 50 to 55, wherein the subject has been diagnosed with MSA at least 1.3 years prior to said administering.
57. The use of any one of claims 50 to 56, wherein the subject developed nOH 1.6 years or more prior to the administration.
58. The use of any one of claims 50 to 57, wherein prior to said administering, said subject has an OSHA composite score of 5 or greater.
59. The use of any one of claims 50 to 58, wherein prior to said administering, said subject has an OSHA Section 1 rating of 7 or greater.
60. The use of any one of claims 50 to 59, wherein prior to said administering, said subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of ≤ 4.
61. The use of any one of claims 50 to 59, wherein prior to said administering, said subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of 4.
62. The use according to any one of claims 50 to 61, wherein aproxetine is administered in the form of the hydrochloride salt.
63. The use of any one of claims 50 to 62, wherein the pharmaceutical composition is administered for at least about 12 months.
64. The use according to any one of claims 50 to 63, wherein the pharmaceutically acceptable carrier comprises one or more of microcrystalline cellulose, lactose and magnesium stearate.
65. Use of aproxetine for treating symptomatic neurogenic orthostatic hypotension (nOH) in an individual with multiple system atrophy (MSA), wherein the individual is diagnosed with MSA as a result of: (a) an Orthostatic Hypotension Assessment Scale (OSHA) composite score of 5 or greater prior to said administration; and / or (b) An OSHA Section 1 rating of 7 or higher prior to said administration.
66. Use of a pharmaceutical composition comprising aproxetine or a pharmaceutically acceptable salt thereof for treating symptomatic neurogenic orthostatic hypotension (nOH) in an individual with multiple system atrophy (MSA), wherein the pharmaceutical composition comprises about 10 mg (free base equivalent) of aproxetine, and wherein administration results in a decrease in at least one of the following: the Orthostatic Hypotension Symptom Assessment (OHSA) composite score, the Orthostatic Hypotension Daily Activities Scale (OHDAS) composite score, the Orthostatic Hypotension Daily Activities Scale (OHDAS) Item 1 score (short-term standing), and the OHDAS Item 3 score (short-term walking).
67. The use according to claim 66, wherein the pharmaceutical composition is administered to the subject orally.
68. The use according to claim 66 or 67, wherein the pharmaceutical composition is administered to the subject once daily.
69. The use according to any one of claims 66 to 68, wherein the subject treated suffers from symptoms of neurogenic orthostatic hypotension in the absence of treatment with the pharmaceutical composition as determined using the Orthostatic Hypotension Assessment Scale (OHSA).
70. The use of any one of claims 66 to 69, wherein the subject has MSA P subtype (MSA-P).
71. The use of any one of claims 66 to 69, wherein the subject has MSA subtype C (MSA-C).
72. The use of any one of claims 66 to 71, wherein prior to treatment, the subject's BP has sustained a decrease of ≥20 mmHg (systolic blood pressure) or ≥10 mmHg (diastolic blood pressure) within 3 minutes of standing as part of an upright stand test or tilted upward ≥60° from a supine position as determined by a tilt table test.
73. The use of any one of claims 66 to 72, wherein prior to treatment, the subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of 4 or less.
74. The use of any one of claims 66 to 73, wherein prior to treatment, the subject has a Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV score of 4.
75. The use of any one of claims 66 to 74, wherein prior to said administering, said subject has an OHSA 1 score of at least 4.
76. The use of any one of claims 66 to 75, wherein the pharmaceutical composition is administered for at least about 12 weeks.
77. The use according to any one of claims 66 to 76, wherein aproxetine is administered as a hydrochloride salt.
78. The use of any one of claims 66 to 77, wherein the pharmaceutically acceptable carrier comprises one or more of microcrystalline cellulose, lactose and magnesium stearate.
